{ "name": "Peptide Access Index", "description": "The Peptide Access Index lists 210 rows with their FDA, 503A compounding, PCAC and WADA 2026 status as of October 4–12, 2026. Each row links its primary sources.", "license": "https://creativecommons.org/licenses/by/4.0/", "license_name": "CC BY 4.0", "attribution": "Ellum, Peptide Access Index", "version": "2026.10.14", "kb_commit": "56e4520dcdcf0fdc0b16e3193a7b013e792471d3", "dateModified": "2026-10-12", "row_count": 210, "columns": [ "id", "canonical_name", "aliases", "status_label", "status_class", "trial_phase", "fda_status", "compounding_503a", "compounding_as_of", "pcac_history", "wada_2026", "prescribable_today", "as_of", "source_urls", "class", "mechanism", "url", "status_key", "row_id", "version", "attribution" ], "rows": [ { "id": "5-amino-1mq", "canonical_name": "5-Amino-1MQ", "aliases": "5-amino-1mq;5 amino 1mq;5-amino-1-methylquinolinium", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026 https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"5-AMINO-1-METHYLQUINOLINIUM\"", "class": "Small molecule (not a peptide)", "mechanism": "NNMT inhibitor marketed for fat loss", "url": "https://ellumclinic.com/peptides/5-amino-1mq", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#5-amino-1mq", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "abaloparatide", "canonical_name": "Abaloparatide", "aliases": "abaloparatide;tymlos", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Tymlos NDA208743, 2017)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8", "class": "PTHrP analog (peptide)", "mechanism": "Activates PTH1 receptor to build bone", "url": "https://ellumclinic.com/peptides/abaloparatide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#abaloparatide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "acarbose", "canonical_name": "Acarbose", "aliases": "acarbose;precose;glucobay", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Precose NDA020482 1995, disc.; generics); label: type 2 diabetes", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=352dd336-d3f9-4ac5-a000-91d3aef7aca3", "class": "Alpha-glucosidase inhibitor (not a peptide)", "mechanism": "Slows carbohydrate digestion in the gut", "url": "https://ellumclinic.com/peptides/acarbose", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#acarbose", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "adamax", "canonical_name": "Adamax (adamantane semax)", "aliases": "adamax peptide;adamax;super semax", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Vendor-designed semax derivative", "mechanism": "Reported by vendors as a semax variant with an adamantane group; no published study", "url": "https://ellumclinic.com/peptides/adamax", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#adamax", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "afamelanotide", "canonical_name": "Afamelanotide", "aliases": "afamelanotide;scenesse;melanotan 1;melanotan i", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Scenesse NDA210797, 2019)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48", "class": "Alpha-MSH analog (peptide implant)", "mechanism": "Raises skin melanin to reduce light-triggered pain", "url": "https://ellumclinic.com/peptides/afamelanotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#afamelanotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ahk-cu", "canonical_name": "AHK-Cu (copper tripeptide)", "aliases": "ahk-cu;ahk cu;ahk-cu peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"AHK-CU\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Copper tripeptide (alanyl-histidyl-lysine copper)", "mechanism": "Copper-binding tripeptide related to GHK-Cu, marketed for hair and skin", "url": "https://ellumclinic.com/peptides/ahk-cu", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ahk-cu", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "alanyl-glutamine", "canonical_name": "Alanyl-L-glutamine", "aliases": "alanyl-l-glutamine;alanyl glutamine;l-alanyl-l-glutamine", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (as a drug)", "compounding_503a": "Category 1 (interim; enforcement discretion); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "2015-10-27/28: voted not to include (vote count not confirmed), FDA proposed exclusion 2019-09-05, never finalized", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.federalregister.gov/d/2019-18951 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Dipeptide", "mechanism": "Stable glutamine source", "url": "https://ellumclinic.com/peptides/alanyl-glutamine", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#alanyl-glutamine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "amycretin", "canonical_name": "Amycretin", "aliases": "amycretin;nnc0487-0111", "status_label": "Investigational (phase 3)", "status_class": "investigational", "trial_phase": "3", "fda_status": "Investigational, phase 3 started 2026 (AMAZE), not filed", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"AMYCRETIN\" https://clinicaltrials.gov/study/NCT07339423 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Unimolecular GLP-1 + amylin agonist (peptide)", "mechanism": "One molecule hitting GLP-1 and amylin receptors", "url": "https://ellumclinic.com/peptides/amycretin", "status_key": "investigational", "row_id": "https://ellumclinic.com/peptides/status#amycretin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "anastrozole", "canonical_name": "Anastrozole", "aliases": "anastrozole;arimidex;adex;anastrazole", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Arimidex NDA020541 1995; generics); label: breast cancer in postmenopausal women. Use in men is off-label", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S4.1 (named Anastrozole)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de https://www.fda.gov/media/94164/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Aromatase inhibitor (not a peptide)", "mechanism": "Blocks the conversion of testosterone to estradiol", "url": "https://ellumclinic.com/peptides/anastrozole", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#anastrozole", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "aod-9604", "canonical_name": "AOD-9604", "aliases": "aod-9604;aod 9604;aod9604;hgh fragment 176-191;hgh frag", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "2024-12-04: against 0-12-0 (group vote; use reviewed: obesity); FDA staff: against", "wada_2026": "S2.2.3", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/185642/download https://www.fda.gov/media/183584/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/innoveix-pharmaceuticals-inc-624782-01262022 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://web.archive.org/web/20241107074712id_/https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"AOD-9604\"", "class": "Growth hormone fragment (peptide)", "mechanism": "Modified tail piece of growth hormone", "url": "https://ellumclinic.com/peptides/aod-9604", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#aod-9604", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "argireline", "canonical_name": "Argireline (acetyl hexapeptide-8)", "aliases": "argireline;acetyl hexapeptide-8;acetyl hexapeptide-3", "status_label": "Cosmetic", "status_class": "cosmetic", "trial_phase": null, "fda_status": "Cosmetic", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94164/download", "class": "Cosmetic neuropeptide", "mechanism": "Peptide used in creams to soften expression lines", "url": "https://ellumclinic.com/peptides/argireline", "status_key": "cosmetic", "row_id": "https://ellumclinic.com/peptides/status#argireline", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "berberine", "canonical_name": "Berberine", "aliases": "berberine;berberine hcl;berberine hydrochloride;natural ozempic;nature's ozempic", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Not an approved drug; sold as a dietary supplement (no FDA statement that it is unlawful found)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "Not named on the 2026 List", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/supersmart-usa-llc-706566-01212026 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Plant isoquinoline alkaloid (botanical supplement)", "mechanism": "Alkaloid from barberry and goldenseal; activates AMPK in lab studies", "url": "https://ellumclinic.com/peptides/berberine", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#berberine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "bivalirudin", "canonical_name": "Bivalirudin", "aliases": "bivalirudin;angiomax", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Angiomax NDA020873, 2000)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a4afc5-151d-4d3c-bfef-48aa8797d695", "class": "Direct thrombin inhibitor (peptide)", "mechanism": "Blocks thrombin to prevent clotting during PCI", "url": "https://ellumclinic.com/peptides/bivalirudin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#bivalirudin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "bpc-157", "canonical_name": "BPC-157", "aliases": "bpc 157;bpc-157;bpc157;body protection compound;pentadecapeptide bpc 157;bpc", "status_label": "Not FDA-approved · advisory vote July 2026 · no FDA decision", "status_class": "under_fda_review", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04", "compounding_as_of": "2026-10-04", "pcac_history": "2026-07-23: recommended 8-6-1 (free base and acetate; use reviewed: ulcerative colitis; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against", "wada_2026": "S0", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193343/download https://www.fda.gov/media/193342/download https://www.fda.gov/media/193711/download https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://youtube.com/live/DhDC0DAYdBI?t=16980", "class": "Synthetic gastric pentadecapeptide", "mechanism": "Lab-made peptide based on a protein said to be in stomach juice, studied in tissue research", "url": "https://ellumclinic.com/peptides/bpc-157", "status_key": "under_fda_review", "row_id": "https://ellumclinic.com/peptides/status#bpc-157", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "bpc-157-ghk-cu-stack", "canonical_name": "BPC-157 / GHK-Cu stack", "aliases": "bpc ghk-cu;bpc-157 ghk-cu", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "Injectable repair/skin stack", "url": "https://ellumclinic.com/peptides/stacks/bpc-157-ghk-cu-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#bpc-157-ghk-cu-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "bpc-157-kpv-stack", "canonical_name": "BPC-157 / KPV stack", "aliases": "bpc kpv;bpc-157 kpv", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193346/download", "class": "Stack of 2 entities", "mechanism": "Gut-focused stack; variants add LL-37 or TB-500", "url": "https://ellumclinic.com/peptides/stacks/bpc-157-kpv-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#bpc-157-kpv-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "bpc-157-thymosin-alpha-1-stack", "canonical_name": "BPC-157 / thymosin alpha-1 stack", "aliases": "bpc-157 thymosin alpha-1;bpc ta1", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"THYMALFASIN\"", "class": "Stack of 2 entities", "mechanism": "Repair + immune stack", "url": "https://ellumclinic.com/peptides/stacks/bpc-157-thymosin-alpha-1-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#bpc-157-thymosin-alpha-1-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "bremelanotide", "canonical_name": "Bremelanotide", "aliases": "bremelanotide;pt-141;pt 141;pt141", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Vyleesi, NDA210557, 2019)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026", "class": "Melanocortin receptor agonist (peptide)", "mechanism": "Ring-shaped peptide that turns on melanocortin receptors in the nervous system", "url": "https://ellumclinic.com/peptides/bremelanotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#bremelanotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "libido-peptide-stack", "canonical_name": "Bremelanotide / oxytocin / kisspeptin-10 stack", "aliases": "libido peptide stack;pt-141 oxytocin;sexual optimization blend", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad https://www.fda.gov/media/94155/download", "class": "Stack of 3 entities", "mechanism": "Sexual-health stack", "url": "https://ellumclinic.com/peptides/stacks/libido-peptide-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#libido-peptide-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "bronchogen", "canonical_name": "Bronchogen", "aliases": "bronchogen;ala-glu-asp-leu", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tetrapeptide (AEDL; one paper says ADEL)", "mechanism": "Four-amino-acid peptide modeled on airway tissue, studied in rodent lung models", "url": "https://ellumclinic.com/peptides/bronchogen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#bronchogen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cagrilintide", "canonical_name": "Cagrilintide", "aliases": "cagrilintide;cagri;cagrilintide peptide", "status_label": "Investigational (phase 3)", "status_class": "investigational", "trial_phase": "3", "fda_status": "Investigational, not filed as monotherapy", "compounding_503a": "Not eligible (FDA: 'cannot be used in compounding under federal law')", "compounding_as_of": "2026-10-01", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"CAGRILINTIDE\" https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025 https://clinicaltrials.gov/study/NCT06065540 https://clinicaltrials.gov/study/NCT07220642", "class": "Long-acting amylin analog (peptide)", "mechanism": "Amylin mimic that slows eating and stomach emptying", "url": "https://ellumclinic.com/peptides/cagrilintide", "status_key": "investigational", "row_id": "https://ellumclinic.com/peptides/status#cagrilintide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cagrilintide-retatrutide-stack", "canonical_name": "Cagrilintide / retatrutide stack", "aliases": "cagri reta;cagri reta stack;cagrilintide retatrutide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025", "class": "Stack of 2 entities", "mechanism": "Investigational incretin + amylin stack", "url": "https://ellumclinic.com/peptides/stacks/cagrilintide-retatrutide-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cagrilintide-retatrutide-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cagrilintide-tirzepatide-stack", "canonical_name": "Cagrilintide / tirzepatide stack", "aliases": "cagri tirz;cagrilintide tirzepatide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "class": "Stack of 2 entities", "mechanism": "Amylin analog added to tirzepatide", "url": "https://ellumclinic.com/peptides/stacks/cagrilintide-tirzepatide-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cagrilintide-tirzepatide-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cagrisema", "canonical_name": "CagriSema (cagrilintide + semaglutide)", "aliases": "cagrisema;cagri sema;cagrilintide semaglutide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Investigational; NDA submitted 2025-12-18 (sponsor), FDA decision pending", "compounding_503a": "Not eligible (cagrilintide component: FDA 'cannot be used in compounding')", "compounding_as_of": "2026-10-01", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"CAGRILINTIDE\" https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://clinicaltrials.gov/study/NCT05567796", "class": "Amylin analog + GLP-1 agonist combination", "mechanism": "Pairs an amylin analog with a GLP-1 agonist", "url": "https://ellumclinic.com/peptides/stacks/cagrisema", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cagrisema", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "calcitonin-salmon", "canonical_name": "Calcitonin salmon", "aliases": "calcitonin;calcitonin salmon;miacalcin", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Miacalcin injection NDA017808, 1986; nasal forms Disc)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89cd4f46-b88a-4c10-b25c-47352280dc4e", "class": "Calcitonin (peptide)", "mechanism": "Slows bone breakdown and lowers blood calcium", "url": "https://ellumclinic.com/peptides/calcitonin-salmon", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#calcitonin-salmon", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cardarine", "canonical_name": "Cardarine (GW501516)", "aliases": "cardarine;gw501516;gw-501516;gw 501516;gw1516;endurobol", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved; FDA WL 719257 calls 'Cardarine GW501516' an unapproved new drug", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S4.4.1 (PPAR-delta agonists; named GW1516, GW501516)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dynamic-health-group-dba-sarms-america-719257-12122025 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "PPAR-delta agonist (not a SARM; sold alongside them)", "mechanism": "Activates the PPAR-delta receptor, shifting muscle toward burning fat", "url": "https://ellumclinic.com/peptides/cardarine", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cardarine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cardiogen", "canonical_name": "Cardiogen (peptide bioregulator)", "aliases": "cardiogen peptide;cardiogen", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tetrapeptide", "mechanism": "Four-amino-acid peptide modeled on heart tissue, studied in rat models", "url": "https://ellumclinic.com/peptides/cardiogen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cardiogen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cartalax", "canonical_name": "Cartalax", "aliases": "cartalax;cartalax peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic peptide (reported by vendors as a tripeptide)", "mechanism": "Peptide sold for cartilage support (vendors list three amino acids); essentially no indexed research", "url": "https://ellumclinic.com/peptides/cartalax", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cartalax", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cerebrolysin", "canonical_name": "Cerebrolysin", "aliases": "cerebrolysin;cerebrolysine;fpf-1070", "status_label": "Approved outside the US", "status_class": "approved_outside_us", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; approved in Austria and Russia, so S0 does not apply", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021 https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Porcine-brain peptide preparation", "mechanism": "Mix of small peptides and amino acids from pig brain, studied after stroke and brain injury", "url": "https://ellumclinic.com/peptides/cerebrolysin", "status_key": "approved_outside_us", "row_id": "https://ellumclinic.com/peptides/status#cerebrolysin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cetrorelix", "canonical_name": "Cetrorelix", "aliases": "cetrorelix;cetrotide", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Cetrotide NDA021197, 2000)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79", "class": "GnRH antagonist (peptide)", "mechanism": "Prevents premature LH surge during IVF", "url": "https://ellumclinic.com/peptides/cetrorelix", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#cetrorelix", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "chonluten", "canonical_name": "Chonluten", "aliases": "chonluten;honluten", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic peptide (reported by vendors as a tripeptide)", "mechanism": "Peptide sold for airway support (vendors list three amino acids)", "url": "https://ellumclinic.com/peptides/chonluten", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#chonluten", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cibinetide", "canonical_name": "Cibinetide (ARA-290)", "aliases": "cibinetide;ara-290;ara 290", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 3 (since 2023-09-29); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "EPO-derived peptide", "mechanism": "Activates the innate repair receptor without raising red cells", "url": "https://ellumclinic.com/peptides/cibinetide", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cibinetide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cjc-1295", "canonical_name": "CJC-1295", "aliases": "cjc-1295;cjc 1295;cjc1295;cjc-1295 dac;cjc 1295 no dac;mod grf 1-29", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "2024-12-04: against (free base 0-13; acetate 1-12; DAC forms 0-13 each; use reviewed: GHD); FDA staff: against", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/185642/download https://www.fda.gov/media/183819/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://web.archive.org/web/20241107074712id_/https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"CJC-1295\"", "class": "GHRH analog (peptide; with or without DAC)", "mechanism": "Long-acting GHRH analog that binds the GHRH receptor", "url": "https://ellumclinic.com/peptides/cjc-1295", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cjc-1295", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cjc-ipamorelin-ghrp-2-blend", "canonical_name": "CJC-1295 / ipamorelin / GHRP-2 blend", "aliases": "mod grf ipamorelin ghrp-2;cjc ipamorelin ghrp-2 blend;gh triple blend", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/185412/download https://www.fda.gov/media/94164/download", "class": "Stack of 3 entities", "mechanism": "Premixed three-peptide GH blend", "url": "https://ellumclinic.com/peptides/stacks/cjc-ipamorelin-ghrp-2-blend", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cjc-ipamorelin-ghrp-2-blend", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cjc-ipamorelin-stack", "canonical_name": "CJC-1295 / ipamorelin stack", "aliases": "cjc ipamorelin;cjc/ipamorelin;cjc ipa stack;cjc-1295 ipamorelin blend", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Neither component has a 503A category (both withdrawn 2024-09-27); ipamorelin acetate is in 503B Category 2", "compounding_as_of": "2026-05-14", "pcac_history": "Components each voted against: ipamorelin 2024-10-29, CJC-1295 2024-12-04", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/185642/download https://www.fda.gov/media/185412/download https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://web.archive.org/web/20241107074712id_/https://www.fda.gov/media/94155/download", "class": "Two-peptide blend", "mechanism": "Pairs a GHRH analog with a GH secretagogue, two signals linked to GH release", "url": "https://ellumclinic.com/peptides/stacks/cjc-ipamorelin-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cjc-ipamorelin-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "clomiphene", "canonical_name": "Clomiphene (clomiphene citrate)", "aliases": "clomiphene;clomiphene citrate;clomid;clomifene;serophene;clomid for men", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Clomid NDA016131 1967, now ANDA075528; generics); label: ovulatory dysfunction in women. Male use is off-label", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S4.2 (named Clomifene)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2ca373c1-4dba-4126-8616-5c533d606fe5 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "SERM (not a peptide)", "mechanism": "Blocks estrogen feedback, raising LH and FSH; triggers ovulation", "url": "https://ellumclinic.com/peptides/clomiphene", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#clomiphene", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "collagen-peptides", "canonical_name": "Collagen peptides (hydrolyzed collagen)", "aliases": "collagen peptides;hydrolyzed collagen;collagen powder;collagen supplement", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Food / dietary supplement", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements https://api.ods.od.nih.gov/dsld/v9/label/246505 https://api.ods.od.nih.gov/dsld/v9/label/241627", "class": "Food protein hydrolysate", "mechanism": "Digested collagen protein as a food/supplement", "url": "https://ellumclinic.com/peptides/collagen-peptides", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#collagen-peptides", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "compounded-semaglutide", "canonical_name": "Compounded semaglutide", "aliases": "compounded semaglutide;compounded ozempic;compounded wegovy;semaglutide b12", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (compounded drugs are not FDA-approved)", "compounding_503a": "Shortage resolved 2025-02-21; 503A only if not 'essentially a copy' (documented prescriber determination) or <=4 Rx/month; not on 503B bulks or shortage list", "compounding_as_of": "2026-04-01", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize https://www.fda.gov/media/185526/download https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "class": "Compounded copy of an approved GLP-1", "mechanism": "Same mechanism as semaglutide", "url": "https://ellumclinic.com/peptides/semaglutide#forms", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#compounded-semaglutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "compounded-tirzepatide", "canonical_name": "Compounded tirzepatide", "aliases": "compounded tirzepatide;compounded mounjaro;compounded zepbound", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (compounded drugs are not FDA-approved)", "compounding_503a": "Shortage resolved 2024-12-19; 503A only if not 'essentially a copy' (documented prescriber determination) or <=4 Rx/month; not on 503B bulks or shortage list", "compounding_as_of": "2026-04-01", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize https://www.fda.gov/media/184606/download https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "class": "Compounded copy of an approved GIP/GLP-1", "mechanism": "Same mechanism as tirzepatide", "url": "https://ellumclinic.com/peptides/tirzepatide#forms", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#compounded-tirzepatide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "coq10", "canonical_name": "CoQ10 / ubiquinol", "aliases": "coq10;coenzyme q10;ubiquinol;ubiquinone", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.nccih.nih.gov/health/coenzyme-q10", "class": "Mitochondrial cofactor (not a peptide)", "mechanism": "Carries electrons in mitochondrial energy production", "url": "https://ellumclinic.com/peptides/coq10", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#coq10", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cortagen", "canonical_name": "Cortagen (peptide bioregulator)", "aliases": "cortagen;cortagen peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"CORTAGEN\" https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic short peptide (Khavinson bioregulator)", "mechanism": "Short peptide sold as a brain-tissue bioregulator; little indexed research", "url": "https://ellumclinic.com/peptides/cortagen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#cortagen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "cortexin", "canonical_name": "Cortexin", "aliases": "cortexin;cortexine;korteksin", "status_label": "Approved outside the US", "status_class": "approved_outside_us", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; approved in Russia, so S0 does not apply", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Animal cerebral-cortex polypeptide extract", "mechanism": "Mixture of small peptides from animal brain cortex, studied as a neuroprotectant", "url": "https://ellumclinic.com/peptides/cortexin", "status_key": "approved_outside_us", "row_id": "https://ellumclinic.com/peptides/status#cortexin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "creatine", "canonical_name": "Creatine monohydrate", "aliases": "creatine;creatine monohydrate;creapure", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&search=creatine&type=basic&sort=GRN_No&order=DESC&startrow=1", "class": "Amino-acid derivative (not a peptide)", "mechanism": "Recycles cellular energy (ATP) in muscle and brain", "url": "https://ellumclinic.com/peptides/creatine", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#creatine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "crystagen", "canonical_name": "Crystagen", "aliases": "crystagen;kristagen", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic peptide (reported by vendors as a tripeptide)", "mechanism": "Peptide sold for immune support (vendors list three amino acids)", "url": "https://ellumclinic.com/peptides/crystagen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#crystagen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "dalargin", "canonical_name": "Dalargin", "aliases": "dalargin;tyr-d-ala-gly-phe-leu-arg", "status_label": "Approved outside the US", "status_class": "approved_outside_us", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; approved in Russia, so S0 does not apply", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Leu-enkephalin analog hexapeptide", "mechanism": "Modified enkephalin acting on opioid receptors mostly outside the brain; used in Russia for ulcers", "url": "https://ellumclinic.com/peptides/dalargin", "status_key": "approved_outside_us", "row_id": "https://ellumclinic.com/peptides/status#dalargin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "dasiglucagon", "canonical_name": "Dasiglucagon", "aliases": "dasiglucagon;zegalogue", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Zegalogue NDA214231, 2021); Drugs@FDA lists both products Discontinued; the only US listing (Novo Nordisk) has a marketing end date of 2027-08-31", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14704879-872c-4967-8779-04a3bbdfb4e6 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214231", "class": "Glucagon analog (peptide)", "mechanism": "Stable glucagon analog for severe hypoglycemia", "url": "https://ellumclinic.com/peptides/dasiglucagon", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#dasiglucagon", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "degarelix", "canonical_name": "Degarelix", "aliases": "degarelix;firmagon", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Firmagon NDA022201, 2008)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab11dd8a-0fd9-4013-89ab-e114557c7e4b", "class": "GnRH antagonist (peptide)", "mechanism": "Blocks GnRH receptors to cut testosterone fast", "url": "https://ellumclinic.com/peptides/degarelix", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#degarelix", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "desmopressin", "canonical_name": "Desmopressin", "aliases": "desmopressin;ddavp;desmoda", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (DDAVP NDA019955; Desmoda 2026)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S5", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Vasopressin analog (peptide)", "mechanism": "Acts on kidney V2 receptors to reduce urine", "url": "https://ellumclinic.com/peptides/desmopressin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#desmopressin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "dhea", "canonical_name": "DHEA (dehydroepiandrosterone, prasterone)", "aliases": "dhea;dehydroepiandrosterone;prasterone;dhea supplement;dhea cream", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx as prasterone (Intrarosa NDA208470, 2016; vaginal insert for menopausal dyspareunia); also sold OTC as a supplement", "compounding_503a": "Approved-drug component (503B Category 1 '**')", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S1.1 (named prasterone/DHEA)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ada639d4-bac0-2ad0-e053-2a95a90afce7 https://www.federalregister.gov/documents/2005/12/16/05-23907/implementation-of-the-anabolic-steroid-control-act-of-2004 https://www.fda.gov/media/94164/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Adrenal steroid / androgen precursor (not a peptide)", "mechanism": "Adrenal steroid the body converts into testosterone and estrogens", "url": "https://ellumclinic.com/peptides/dhea", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#dhea", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "difelikefalin", "canonical_name": "Difelikefalin", "aliases": "difelikefalin;korsuva", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Korsuva NDA214916, 2021)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c7b81f2-0fd3-47cb-8b0f-185e07f19c87", "class": "Peripheral kappa-opioid agonist (peptide)", "mechanism": "Calms itch nerves without entering the brain", "url": "https://ellumclinic.com/peptides/difelikefalin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#difelikefalin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "dihexa", "canonical_name": "Dihexa", "aliases": "dihexa;dihexa acetate;pnb-0408", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "Scheduled: PCAC 'before the end of February 2027' (no date set)", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"DIHEXA\"", "class": "Angiotensin IV analog (peptide-derived)", "mechanism": "Studied for cognition via HGF/c-Met signaling", "url": "https://ellumclinic.com/peptides/dihexa", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#dihexa", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "dulaglutide", "canonical_name": "Dulaglutide", "aliases": "dulaglutide;trulicity", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Trulicity BLA125469, 2014)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309", "class": "GLP-1 receptor agonist (Fc-fusion peptide)", "mechanism": "Weekly GLP-1 mimic for type 2 diabetes", "url": "https://ellumclinic.com/peptides/dulaglutide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#dulaglutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "egrifta", "canonical_name": "Egrifta", "aliases": "egrifta;egrifta sv;egrifta wr", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (BLA022505, 2010; current Egrifta WR and SV; HIV lipodystrophy abdominal fat)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224", "class": "Brand of tesamorelin", "mechanism": "See tesamorelin", "url": "https://ellumclinic.com/peptides/tesamorelin#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#egrifta", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "elamipretide", "canonical_name": "Elamipretide", "aliases": "elamipretide;ss-31;ss 31;ss31", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Forzinity NDA215244, 2025-09-19, accelerated approval)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75 https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026", "class": "Mitochondria-targeted tetrapeptide", "mechanism": "Binds cardiolipin in the inner mitochondrial membrane", "url": "https://ellumclinic.com/peptides/elamipretide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#elamipretide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "eloralintide", "canonical_name": "Eloralintide", "aliases": "eloralintide;eloralintide peptide;ly3841136", "status_label": "Investigational (phase 3)", "status_class": "investigational", "trial_phase": "3", "fda_status": "Investigational, phase 3 (Eli Lilly); no FDA approval record", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://clinicaltrials.gov/study/NCT07282600 https://clinicaltrials.gov/study/NCT07321886 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"ELORALINTIDE\" https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Amylin receptor agonist (peptide)", "mechanism": "Long-acting amylin mimic studied for weight loss", "url": "https://ellumclinic.com/peptides/eloralintide", "status_key": "investigational", "row_id": "https://ellumclinic.com/peptides/status#eloralintide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "emideltide", "canonical_name": "Emideltide (DSIP)", "aliases": "dsip;delta sleep inducing peptide;emideltide;delta sleep-inducing peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "2026-07-24: NOT recommended 6-7-1 (free base and acetate; uses reviewed: opioid withdrawal, chronic insomnia, narcolepsy; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193344/download https://www.fda.gov/media/193342/download https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://youtube.com/live/xXM5ecHxlMU?t=11711 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"EMIDELTIDE\"", "class": "Nonapeptide", "mechanism": "Small neuropeptide made of nine amino acids", "url": "https://ellumclinic.com/peptides/emideltide", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#emideltide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "enclomiphene", "canonical_name": "Enclomiphene (enclomiphene citrate)", "aliases": "enclomiphene;enclomiphene citrate;enclomifene;androxal;enclomid", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (openFDA: no application)", "compounding_503a": "Category 1 (503A, interim); FDA proposed NOT listing it and PCAC voted 4-8 against (2022-06-08); FDA: not an approved-drug component. Not in 503B; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "PCAC 2022-06-08: 4-8 against; FDA staff: against", "wada_2026": "S4.2 by class (SERMs; not named)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/161293/download https://www.federalregister.gov/documents/2022/05/06/2022-09797/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"ENCLOMIPHENE\" https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "SERM (trans-isomer of clomiphene; not a peptide)", "mechanism": "Blocks estrogen feedback in the brain, raising LH, FSH and the body's own testosterone", "url": "https://ellumclinic.com/peptides/enclomiphene", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#enclomiphene", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "epitalon", "canonical_name": "Epitalon", "aliases": "epitalon;epithalon;epithalone;ala-glu-asp-gly;aedg", "status_label": "Not FDA-approved · advisory vote July 2026 · no FDA decision", "status_class": "under_fda_review", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04", "compounding_as_of": "2026-10-04", "pcac_history": "2026-07-24: recommended 7-4-1 (free base and acetate; use reviewed: insomnia; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193345/download https://www.fda.gov/media/193342/download https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://youtube.com/live/xXM5ecHxlMU?t=17666", "class": "Synthetic tetrapeptide", "mechanism": "Lab-made four-amino-acid peptide based on a pineal gland extract", "url": "https://ellumclinic.com/peptides/epitalon", "status_key": "under_fda_review", "row_id": "https://ellumclinic.com/peptides/status#epitalon", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "fountain-of-youth-stack", "canonical_name": "Epitalon / GHK-Cu stack", "aliases": "", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "Longevity/skin stack", "url": "https://ellumclinic.com/peptides/stacks/fountain-of-youth-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#fountain-of-youth-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "epitalon-pinealon-stack", "canonical_name": "Epitalon / pinealon stack", "aliases": "epitalon pinealon;epithalon pinealon", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "Khavinson-style bioregulator stack", "url": "https://ellumclinic.com/peptides/stacks/epitalon-pinealon-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#epitalon-pinealon-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "epitalon-thymalin-stack", "canonical_name": "Epitalon / thymalin stack", "aliases": "epitalon thymalin;khavinson stack", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024", "class": "Stack of 2 entities", "mechanism": "Khavinson bioregulator stack (pineal + thymus)", "url": "https://ellumclinic.com/peptides/stacks/epitalon-thymalin-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#epitalon-thymalin-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "epithalamin", "canonical_name": "Epithalamin (pineal extract)", "aliases": "epithalamin;epithalamine;epitalamin", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/193345/download https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Bovine pineal polypeptide extract", "mechanism": "Peptide mixture from cattle pineal glands; parent extract of synthetic Epitalon", "url": "https://ellumclinic.com/peptides/epithalamin", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#epithalamin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "estradiol", "canonical_name": "Estradiol", "aliases": "estradiol;oestradiol;estrace;estradiol patch;climara;vivelle-dot;estradiol cypionate;estradiol valerate;estradiol cream;estradiol gel;divigel;vagifem;estring;bioidentical estrogen", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Climara NDA020375; Estrace ANDA086069; Depo-Estradiol ANDA085470; hundreds of products); label: menopausal vasomotor symptoms, vulvar/vaginal atrophy, hypoestrogenism. Boxed warning", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864 https://www.fda.gov/media/94164/download", "class": "Estrogen (not a peptide)", "mechanism": "The main human estrogen, used as hormone replacement", "url": "https://ellumclinic.com/peptides/estradiol", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#estradiol", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "exenatide", "canonical_name": "Exenatide", "aliases": "exenatide;byetta;bydureon;bydureon bcise", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Byetta NDA021919 listed Rx; NDA021773 Disc; Bydureon/BCise Disc)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f", "class": "GLP-1 receptor agonist (peptide)", "mechanism": "Exendin-4 analog; GLP-1 mimic for type 2 diabetes", "url": "https://ellumclinic.com/peptides/exenatide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#exenatide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "finasteride", "canonical_name": "Finasteride", "aliases": "finasteride;propecia;proscar;topical finasteride", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Proscar NDA020180 1992, BPH; Propecia NDA020788 1997, male pattern hair loss, men only); no approved topical found", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f988153-fc74-4ca4-b29a-111f750c4a4b", "class": "5-alpha-reductase inhibitor (not a peptide)", "mechanism": "Blocks the conversion of testosterone to DHT", "url": "https://ellumclinic.com/peptides/finasteride", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#finasteride", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "fisetin", "canonical_name": "Fisetin", "aliases": "fisetin", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Not an approved drug; sold as a dietary supplement", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/193536/download https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/synaptent-llc-610683-11092021", "class": "Plant flavonol (polyphenol)", "mechanism": "Flavonoid from strawberries; studied as a 'senolytic' in animals", "url": "https://ellumclinic.com/peptides/fisetin", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#fisetin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "follistatin", "canonical_name": "Follistatin", "aliases": "follistatin;follistatin 344;fs-344", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S4.3", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"FOLLISTATIN\"", "class": "Myostatin-binding protein", "mechanism": "Binds myostatin, a brake on muscle growth", "url": "https://ellumclinic.com/peptides/follistatin", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#follistatin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "forzinity", "canonical_name": "Forzinity", "aliases": "forzinity", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA215244, 2025-09-19, accelerated approval; Barth syndrome)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75 https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome", "class": "Brand of elamipretide", "mechanism": "See elamipretide", "url": "https://ellumclinic.com/peptides/elamipretide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#forzinity", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "foundayo", "canonical_name": "Foundayo", "aliases": "foundayo", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA220934, 2026-04-01)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "class": "Brand of orforglipron", "mechanism": "See orforglipron", "url": "https://ellumclinic.com/peptides/orforglipron#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#foundayo", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "foxo4-dri", "canonical_name": "FOXO4-DRI", "aliases": "foxo4-dri;foxo4 dri;foxo4-dri peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"FOXO4-DRI\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "D-retro-inverso peptide (FOXO4-derived)", "mechanism": "Designed to block FOXO4 binding to p53 in senescent cells; studied as a senolytic in mice", "url": "https://ellumclinic.com/peptides/foxo4-dri", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#foxo4-dri", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ganirelix", "canonical_name": "Ganirelix", "aliases": "ganirelix;antagon", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (ganirelix acetate NDA021057, 1999)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=32fb74ff-993a-49fe-8943-e029372b863e", "class": "GnRH antagonist (peptide)", "mechanism": "Prevents premature LH surge during IVF", "url": "https://ellumclinic.com/peptides/ganirelix", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#ganirelix", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "gh-triple-stack", "canonical_name": "GH triple stack (CJC-1295 + ipamorelin + sermorelin)", "aliases": "growth hormone triple stack;gh triple stack", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/185412/download https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863", "class": "Stack of 3 entities", "mechanism": "Pairs two GHRH analogs with a ghrelin agonist", "url": "https://ellumclinic.com/peptides/stacks/gh-triple-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#gh-triple-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ghk-cu", "canonical_name": "GHK-Cu (copper tripeptide)", "aliases": "ghk-cu;ghk cu;copper peptide;copper tripeptide-1;glycyl-l-histidyl-l-lysine copper", "status_label": "Cosmetic", "status_class": "cosmetic", "trial_phase": null, "fda_status": "Not FDA-approved as a drug; cosmetic ingredient (topical)", "compounding_503a": "Non-injectable: Category 1 (removed 2026-04-22; 'will be added back'); injectable: no category", "compounding_as_of": "2026-05-14", "pcac_history": "Scheduled: PCAC 'before the end of February 2027' (no date set)", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download", "class": "Copper tripeptide (glycyl-histidyl-lysine copper)", "mechanism": "Copper-binding tripeptide found in plasma", "url": "https://ellumclinic.com/peptides/ghk-cu", "status_key": "cosmetic", "row_id": "https://ellumclinic.com/peptides/status#ghk-cu", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ghk-cu-injectable", "canonical_name": "GHK-Cu (injectable)", "aliases": "ghk-cu injection;ghk-cu injectable;copper peptide injection;ghk cu vial", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component (injectable routes)", "compounding_as_of": "2026-10-07", "pcac_history": "Scheduled: PCAC 'before the end of February 2027' (no date set)", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"GHK-CU\"", "class": "Copper tripeptide (glycyl-histidyl-lysine copper)", "mechanism": "Copper-binding tripeptide studied for skin and tissue repair", "url": "https://ellumclinic.com/peptides/ghk-cu#forms", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ghk-cu-injectable", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ghk-cu-topical", "canonical_name": "GHK-Cu (topical cosmetic)", "aliases": "ghk-cu serum;ghk-cu cream;copper peptide serum", "status_label": "Cosmetic", "status_class": "cosmetic", "trial_phase": null, "fda_status": "Cosmetic (not a drug when sold with appearance claims)", "compounding_503a": "Category 1 for non-injectable compounding (removed 2026-04-22; FDA says 'will be added back', 2026-05-14 PDF)", "compounding_as_of": "2026-05-14", "pcac_history": "Scheduled: PCAC 'before the end of February 2027' (no date set)", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap", "class": "Copper tripeptide (cosmetic ingredient)", "mechanism": "Copper-binding tripeptide used in skin and hair care", "url": "https://ellumclinic.com/peptides/ghk-cu#forms", "status_key": "cosmetic", "row_id": "https://ellumclinic.com/peptides/status#ghk-cu-topical", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "hair-growth-peptide-stack", "canonical_name": "GHK-Cu / thymulin / PTD-DBM stack", "aliases": "hair growth peptide stack;hair peptide stack", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Stack of 3 entities", "mechanism": "Topical hair stack", "url": "https://ellumclinic.com/peptides/stacks/hair-growth-peptide-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#hair-growth-peptide-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ghrp-2", "canonical_name": "GHRP-2 (pralmorelin)", "aliases": "ghrp-2;ghrp 2;ghrp2;pralmorelin", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 3; 503B Category 2 (injectable/nasal), 503B Category 1 (other routes); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "GH-releasing peptide", "mechanism": "Ghrelin-receptor agonist that releases GH", "url": "https://ellumclinic.com/peptides/ghrp-2", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ghrp-2", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ghrp-6", "canonical_name": "GHRP-6", "aliases": "ghrp-6;ghrp 6;ghrp6", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 3; 503B Category 2 (since 2023-09-29); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "GH-releasing peptide", "mechanism": "Ghrelin-receptor agonist that releases GH and raises hunger", "url": "https://ellumclinic.com/peptides/ghrp-6", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ghrp-6", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "glow-blend", "canonical_name": "GLOW blend (GHK-Cu + BPC-157 + TB-500)", "aliases": "glow peptide;glow blend;glow stack;glow peptide blend", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Contains GHK-Cu injectable (no category; withdrawn 2026-04-22)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S0 (BPC-157); S2.3 (TB-500)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Three-peptide injectable blend", "mechanism": "Three linear peptides combined in one blend", "url": "https://ellumclinic.com/peptides/stacks/glow-blend", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#glow-blend", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "glucagon", "canonical_name": "Glucagon", "aliases": "glucagon;gvoke;baqsimi;glucagon kit", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Lilly NDA012122 1960; Gvoke NDA212097; Baqsimi)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92385737-dbad-98c5-e053-2995a90a2805", "class": "Pancreatic hormone (peptide)", "mechanism": "Raises blood sugar by releasing liver glycogen", "url": "https://ellumclinic.com/peptides/glucagon", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#glucagon", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "glutathione", "canonical_name": "Glutathione", "aliases": "glutathione;gsh;l-glutathione;reduced glutathione", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA) when oral; injectable is the glutathione-injectable row", "compounding_503a": "Category 1 (503A, injectable compounding)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download", "class": "Tripeptide antioxidant (gamma-Glu-Cys-Gly)", "mechanism": "The body's main antioxidant tripeptide", "url": "https://ellumclinic.com/peptides/glutathione", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#glutathione", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "glutathione-injectable", "canonical_name": "Glutathione (injectable/IV)", "aliases": "glutathione injection;iv glutathione;glutathione iv;glutathione push;gsh injection", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 1 (interim; enforcement discretion); 503B Category 1", "compounding_as_of": "2026-05-14", "pcac_history": "2022-06-08: 8-5-1 in favor of inclusion (no rule since); FDA staff: against", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/161293/download https://www.fda.gov/media/94164/download", "class": "Tripeptide antioxidant", "mechanism": "Major cellular antioxidant (glutamate-cysteine-glycine)", "url": "https://ellumclinic.com/peptides/glutathione#forms", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#glutathione-injectable", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "glutathione-oral", "canonical_name": "Glutathione (oral)", "aliases": "oral glutathione;liposomal glutathione", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=293", "class": "Tripeptide antioxidant (oral supplement)", "mechanism": "Antioxidant taken by mouth", "url": "https://ellumclinic.com/peptides/glutathione#forms", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#glutathione-oral", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "glycine", "canonical_name": "Glycine", "aliases": "glycine", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.govinfo.gov/content/pkg/CFR-2025-title21-vol3/xml/CFR-2025-title21-vol3-sec172-812.xml", "class": "Amino acid", "mechanism": "Building block of collagen and glutathione", "url": "https://ellumclinic.com/peptides/glycine", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#glycine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "glynac", "canonical_name": "GlyNAC (glycine + NAC)", "aliases": "glynac;glycine nac", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement under FDA enforcement discretion (NAC)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.govinfo.gov/content/pkg/CFR-2025-title21-vol3/xml/CFR-2025-title21-vol3-sec172-812.xml https://www.federalregister.gov/documents/2022/08/02/2022-16499/policy-regarding-n-acetyl-l-cysteine-guidance-for-industry-availability https://www.fda.gov/food/hfp-constituent-updates/fda-issues-response-two-citizen-petitions-nac-dietary-supplements", "class": "Glycine + NAC combination", "mechanism": "Two glutathione building blocks", "url": "https://ellumclinic.com/peptides/stacks/glynac", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#glynac", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "gonadorelin", "canonical_name": "Gonadorelin", "aliases": "gonadorelin;factrel;lutrepulse;gnrh;gonadorelin acetate", "status_label": "FDA-approved, discontinued", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Approved for people as Factrel in 1982 and Lutrepulse in 1989. Both have since been discontinued. The federal drug label site DailyMed lists gonadorelin only in drugs for animals", "compounding_503a": "No 503A category; 503B Category 1 as approved-drug component", "compounding_as_of": "2025-03-21", "pcac_history": "", "wada_2026": "S2.2.1 (males)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018123 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019687 https://www.fda.gov/media/94164/download https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "GnRH (peptide)", "mechanism": "Native GnRH; pulses stimulate LH and FSH release", "url": "https://ellumclinic.com/peptides/gonadorelin", "status_key": "approval_discontinued", "row_id": "https://ellumclinic.com/peptides/status#gonadorelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "goserelin", "canonical_name": "Goserelin", "aliases": "goserelin;zoladex", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Zoladex NDA019726, 1989)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.2.1 (males)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=294b168b-6e5f-4db9-bf70-d599271458b3 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "GnRH agonist (peptide implant)", "mechanism": "Implant that suppresses sex hormones", "url": "https://ellumclinic.com/peptides/goserelin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#goserelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "hexarelin", "canonical_name": "Hexarelin (examorelin)", "aliases": "hexarelin;examorelin", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"EXAMORELIN\"", "class": "GH-releasing peptide", "mechanism": "Ghrelin-receptor agonist that releases GH", "url": "https://ellumclinic.com/peptides/hexarelin", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#hexarelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "hcg", "canonical_name": "Human chorionic gonadotropin (hCG)", "aliases": "hcg;chorionic gonadotropin;novarel;pregnyl;human chorionic gonadotropin", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Novarel, Pregnyl; current DailyMed labels)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.2.1 (males)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac6918ff-9dc3-40d9-8619-54b26e4bdfc8 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e94155f-19be-4944-b197-be4edbb4faf9 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Glycoprotein hormone (not a short peptide)", "mechanism": "Mimics LH to stimulate testes/ovaries", "url": "https://ellumclinic.com/peptides/hcg", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#hcg", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ibutamoren", "canonical_name": "Ibutamoren (MK-677)", "aliases": "ibutamoren;mk-677;mk 677;mk677;ibutamoren mesylate", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 2 (since 2023-09-29); 503B Category 2 (since 2022-12-29); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "2024-10-29: against 1-13-0; FDA staff: against", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/185412/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/warrior-labz-sarms-655280-06122023 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Oral GH secretagogue (non-peptide)", "mechanism": "Non-peptide ghrelin-receptor agonist studied in research on GH and IGF-1", "url": "https://ellumclinic.com/peptides/ibutamoren", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ibutamoren", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "icatibant", "canonical_name": "Icatibant", "aliases": "icatibant;firazyr", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Firazyr NDA022150, 2011; generics)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed6657ca-ab68-477a-9968-e12dc928b540", "class": "Bradykinin B2 receptor antagonist (peptide)", "mechanism": "Blocks bradykinin swelling in HAE attacks", "url": "https://ellumclinic.com/peptides/icatibant", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#icatibant", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "igf-1-lr3", "canonical_name": "IGF-1 LR3", "aliases": "igf-1 lr3;igf1 lr3;igf-1lr3;long r3 igf-1", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S2.3", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"IGF-1%20LR3\"", "class": "Modified IGF-1 analog (protein)", "mechanism": "Long-acting IGF-1 analog marketed for muscle", "url": "https://ellumclinic.com/peptides/igf-1-lr3", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#igf-1-lr3", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ipamorelin", "canonical_name": "Ipamorelin", "aliases": "ipamorelin;ipamorelin acetate;ipa", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component; 503B Category 2", "compounding_as_of": "2026-10-07", "pcac_history": "2024-10-29: against 0-12-1 (free base and acetate; uses reviewed: GHD, postoperative ileus); FDA staff: against", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/185412/download https://www.fda.gov/media/182088/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/media/94164/download https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://web.archive.org/web/20241107074712id_/https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"IPAMORELIN\"", "class": "GH secretagogue pentapeptide", "mechanism": "Ghrelin-receptor agonist that releases GH", "url": "https://ellumclinic.com/peptides/ipamorelin", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ipamorelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "kisspeptin-10", "canonical_name": "Kisspeptin-10", "aliases": "kisspeptin;kisspeptin-10;kisspeptin 10;kp-10", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 2 (since 2023-09-29); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "2024-10-29: against 0-11-0 (use reviewed: male secondary hypogonadism); FDA staff: against", "wada_2026": "S2.2.1 (males)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/185412/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Kisspeptin fragment (peptide)", "mechanism": "Studied for stimulating reproductive hormone release (GnRH, then LH) in people", "url": "https://ellumclinic.com/peptides/kisspeptin-10", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#kisspeptin-10", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "klotho", "canonical_name": "Klotho (protein)", "aliases": "klotho;klotho peptide;klotho protein", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"KLOTHO\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Protein (longevity-associated hormone; FGF23 co-receptor)", "mechanism": "Kidney-made protein whose circulating form is studied in aging models", "url": "https://ellumclinic.com/peptides/klotho", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#klotho", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "klow-blend", "canonical_name": "KLOW blend", "aliases": "klow peptide;klow blend;klow stack", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Contains GHK-Cu injectable (no category; withdrawn 2026-04-22)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Multi-peptide injectable blend", "mechanism": "RUO vendor blend; composition varies by seller", "url": "https://ellumclinic.com/peptides/stacks/klow-blend", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#klow-blend", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "kpv", "canonical_name": "KPV", "aliases": "kpv;kpv peptide;lys-pro-val;alpha-msh 11-13", "status_label": "Not FDA-approved · advisory vote July 2026 · no FDA decision", "status_class": "under_fda_review", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04", "compounding_as_of": "2026-10-04", "pcac_history": "2026-07-23: recommended 8-6-1 (free base and acetate; uses reviewed: wound healing, inflammatory conditions; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193346/download https://www.fda.gov/media/193342/download https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://youtube.com/live/DhDC0DAYdBI?t=25590", "class": "Alpha-MSH C-terminal tripeptide", "mechanism": "Tripeptide matching the tail end of the hormone alpha-MSH", "url": "https://ellumclinic.com/peptides/kpv", "status_key": "under_fda_review", "row_id": "https://ellumclinic.com/peptides/status#kpv", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "l-carnitine", "canonical_name": "L-Carnitine (levocarnitine)", "aliases": "l-carnitine;l carnitine;levocarnitine;l-carnitine injection", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx as levocarnitine (Carnitor tablets NDA018948 1985, oral solution NDA019257 1986, injection NDA020182 1992; generics); also sold as a dietary supplement", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-07", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2133bc3-9c15-48bd-8b16-b8995a6a14cd https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf801cc4-775e-433d-9d32-e5d9a98981d3 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018948 https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Amino-acid derivative (not a peptide)", "mechanism": "Carries fatty acids into mitochondria to be burned for energy", "url": "https://ellumclinic.com/peptides/l-carnitine", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#l-carnitine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "l-carnosine", "canonical_name": "L-Carnosine", "aliases": "carnosine;l-carnosine", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (as a drug)", "compounding_503a": "Category 3; 503B Category 3; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Dipeptide (beta-alanyl-histidine)", "mechanism": "Muscle dipeptide that buffers acid", "url": "https://ellumclinic.com/peptides/l-carnosine", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#l-carnosine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "lanreotide", "canonical_name": "Lanreotide", "aliases": "lanreotide;somatuline depot", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Somatuline Depot NDA022074, 2007)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e4a41fd-a753-4362-87ee-8cc56ed3660d", "class": "Somatostatin analog (peptide)", "mechanism": "Long-acting suppression of GH and tumor hormone release", "url": "https://ellumclinic.com/peptides/lanreotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#lanreotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "leuprolide", "canonical_name": "Leuprolide", "aliases": "leuprolide;leuprorelin;lupron;lupron depot;eligard;fensolvi;camcevi", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Lupron NDA019010 1985, Disc; Lupron Depot NDA019732; others)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.2.1 (males)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbc8f94e-7330-4465-05ad-16d64493a5dd https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "GnRH agonist (peptide)", "mechanism": "Over-stimulates then shuts down pituitary sex-hormone signaling", "url": "https://ellumclinic.com/peptides/leuprolide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#leuprolide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "lgd-4033", "canonical_name": "LGD-4033 (ligandrol)", "aliases": "lgd-4033;lgd4033;lgd 4033;ligandrol;vk5211;anabolicum", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved; excluded from the dietary supplement definition under 201(ff)(3) (FDA ingredient directory categories 2, 4)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S1.2 (named LGD-4033 (ligandrol))", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/food/dietary-supplements/information-select-dietary-supplement-ingredients-and-other-substances https://www.fda.gov/consumers/consumer-updates/fda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pinnacle-professional-research-dba-pinnacle-peptides-719337-12122025 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/warrior-labz-sarms-655280-06122023 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Selective androgen receptor modulator (SARM), non-steroidal", "mechanism": "Non-steroidal pill that binds the androgen receptor in a selective way", "url": "https://ellumclinic.com/peptides/lgd-4033", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#lgd-4033", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "linaclotide", "canonical_name": "Linaclotide", "aliases": "linaclotide;linzess", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Linzess NDA202811, 2012)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3", "class": "Guanylate cyclase-C agonist (oral peptide)", "mechanism": "Draws fluid into the gut to relieve constipation", "url": "https://ellumclinic.com/peptides/linaclotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#linaclotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "liraglutide", "canonical_name": "Liraglutide", "aliases": "liraglutide;generic liraglutide;xultophy", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Victoza NDA022341 2010; Saxenda NDA206321 2014; generic ANDA215503 2024)", "compounding_503a": "Approved-drug component; liraglutide injection 'Currently in Shortage' on FDA DSP (checked 2026-10-04); no enforcement-discretion window found", "compounding_as_of": "2026-10-04", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide%20Injection&st=c https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal", "class": "GLP-1 receptor agonist (peptide)", "mechanism": "Copies the gut hormone GLP-1 and binds its receptor, with a lipid attached", "url": "https://ellumclinic.com/peptides/liraglutide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#liraglutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "livagen", "canonical_name": "Livagen (Lys-Glu-Asp-Ala)", "aliases": "livagen;lys-glu-asp-ala", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tetrapeptide (KEDA)", "mechanism": "Four-amino-acid peptide modeled on liver extract, studied in lab models", "url": "https://ellumclinic.com/peptides/livagen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#livagen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ll-37", "canonical_name": "LL-37 (cathelicidin)", "aliases": "ll-37;ll37;ll 37;cathelicidin;cathelicidin ll-37", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "Scheduled: PCAC 'before the end of February 2027' (no date set)", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"LL-37\"", "class": "Antimicrobial peptide (37-aa)", "mechanism": "Human host-defense peptide", "url": "https://ellumclinic.com/peptides/ll-37", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ll-37", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "low-dose-naltrexone", "canonical_name": "Low-dose naltrexone (LDN)", "aliases": "ldn;low dose naltrexone;low-dose naltrexone", "status_label": "Not FDA-approved for this use", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx for naltrexone alone only as tablets (ReVia NDA018932 1984, disc.; generic 50 mg ANDAs; SpecGx ANDA076264 also lists 25 and 100 mg) and Vivitrol NDA021897 2006; no naltrexone-alone product below 25 mg is approved. Contrave NDA200063 2014 pairs naltrexone 8 mg with bupropion 90 mg per tablet for weight management (not a low-dose naltrexone product). Low dose is compounded/off-label. No FDA statement on LDN found", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94164/download https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076264 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200063 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021897 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018932", "class": "Opioid antagonist (not a peptide)", "mechanism": "Blocks opioid receptors; low doses are used off-label with no labeled mechanism", "url": "https://ellumclinic.com/peptides/low-dose-naltrexone", "status_key": "approval_other_use", "row_id": "https://ellumclinic.com/peptides/status#low-dose-naltrexone", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "macimorelin", "canonical_name": "Macimorelin", "aliases": "macimorelin;macrilen", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Macrilen NDA205598, 2017); Drugs@FDA lists Disc", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.2.4", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6034c9b8-5a36-4961-a5dd-11ebf7bdab78 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Ghrelin receptor agonist (oral peptidomimetic)", "mechanism": "Stimulates GH release to test for GH deficiency", "url": "https://ellumclinic.com/peptides/macimorelin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#macimorelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "maridebart-cafraglutide", "canonical_name": "Maridebart cafraglutide (MariTide)", "aliases": "maridebart cafraglutide;maritide;amg 133;cafraglutide", "status_label": "Investigational (phase 3)", "status_class": "investigational", "trial_phase": "3", "fda_status": "Investigational, phase 3 (MARITIME), not filed", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"MARIDEBART%20CAFRAGLUTIDE\" https://clinicaltrials.gov/study/NCT06858839 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "GIPR antagonist + GLP-1 agonist antibody-peptide conjugate", "mechanism": "Antibody blocks GIP receptor while attached peptides activate GLP-1", "url": "https://ellumclinic.com/peptides/maridebart-cafraglutide", "status_key": "investigational", "row_id": "https://ellumclinic.com/peptides/status#maridebart-cafraglutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "matrixyl", "canonical_name": "Matrixyl (palmitoyl pentapeptide-4)", "aliases": "matrixyl;palmitoyl pentapeptide-4;palmitoyl pentapeptide;pal-kttks", "status_label": "Cosmetic", "status_class": "cosmetic", "trial_phase": null, "fda_status": "Cosmetic", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap", "class": "Cosmetic signal peptide", "mechanism": "Lipid-tagged peptide used in anti-wrinkle creams", "url": "https://ellumclinic.com/peptides/matrixyl", "status_key": "cosmetic", "row_id": "https://ellumclinic.com/peptides/status#matrixyl", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "mazdutide", "canonical_name": "Mazdutide", "aliases": "mazdutide;ibi362;ly3305677", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved; no US phase 3 or filing (China trials)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"MAZDUTIDE\" https://clinicaltrials.gov/study/NCT06184568 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "GLP-1/glucagon dual agonist (peptide)", "mechanism": "Activates GLP-1 and glucagon receptors", "url": "https://ellumclinic.com/peptides/mazdutide", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#mazdutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "mecasermin", "canonical_name": "Mecasermin", "aliases": "mecasermin;increlex;igf-1;rhigf-1", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Increlex BLA021839, 2005)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.3", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8b27a1b-a611-4f91-ad22-76d4b390c3ae https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Recombinant IGF-1 (protein)", "mechanism": "Replaces IGF-1 in severe primary IGF-1 deficiency", "url": "https://ellumclinic.com/peptides/mecasermin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#mecasermin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "mgf", "canonical_name": "Mechano growth factor (MGF)", "aliases": "mgf;mechano growth factor;igf-1ec", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 3 (since 2023-09-29); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S2.3", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "IGF-1 splice-variant peptide", "mechanism": "IGF-1 variant linked to muscle repair signaling", "url": "https://ellumclinic.com/peptides/mgf", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#mgf", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "melanotan-ii", "canonical_name": "Melanotan II", "aliases": "melanotan 2;melanotan ii;mt2;mt-2;mt-ii;tanning peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "Scheduled: PCAC 'before the end of February 2027' (no date set)", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"MELANOTAN%20II\"", "class": "Alpha-MSH analog (cyclic peptide)", "mechanism": "Melanocortin agonist that darkens skin and affects libido", "url": "https://ellumclinic.com/peptides/melanotan-ii", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#melanotan-ii", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "metformin", "canonical_name": "Metformin", "aliases": "metformin;metformin hydrochloride;glucophage;glucophage xr;metformin er;metformin longevity;metformin for aging", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Glucophage NDA020357 1995, disc.; 200+ ANDAs); label: type 2 diabetes. Boxed warning: lactic acidosis", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named on the 2026 List", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=011de1a5-1ac0-4831-9e8d-26ec79ba2205 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Biguanide (not a peptide)", "mechanism": "Lowers glucose output by the liver and improves insulin sensitivity", "url": "https://ellumclinic.com/peptides/metformin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#metformin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "methylcobalamin-injection", "canonical_name": "Methylcobalamin injection (methyl B12)", "aliases": "methylcobalamin;methyl b12;methylcobalamin injection;methyl b12 shot;mecobalamin", "status_label": "Not FDA-approved · advisory vote June 2021 · no FDA decision", "status_class": "under_fda_review", "trial_phase": null, "fda_status": "Not FDA-approved as a drug (openFDA: no application)", "compounding_503a": "Category 1 (503A); PCAC recommended 2021-06-09 (9-5; FDA staff: against); no proposed rule as of 2026-10-07; 503B Category 1", "compounding_as_of": "2026-10-07", "pcac_history": "PCAC 2021-06-09: 9-5 for; FDA staff: against", "wada_2026": "Not named", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.federalregister.gov/documents/2021/05/07/2021-09621/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://web.archive.org/web/20241109001606id_/https://www.fda.gov/media/151410/download https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=methylcobalamin", "class": "Vitamin (B12 coenzyme form)", "mechanism": "Coenzyme form of vitamin B12", "url": "https://ellumclinic.com/peptides/methylcobalamin-injection", "status_key": "under_fda_review", "row_id": "https://ellumclinic.com/peptides/status#methylcobalamin-injection", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "methylene-blue", "canonical_name": "Methylene blue (as longevity product)", "aliases": "methylene blue;methylene blue longevity;methylene blue drops;provayblue", "status_label": "Not FDA-approved for this use", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx only as IV injection for acquired methemoglobinemia (ProvayBlue; generics)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204630", "class": "Phenothiazine dye (small molecule, not a peptide)", "mechanism": "Redox dye; accepts and donates electrons", "url": "https://ellumclinic.com/peptides/methylene-blue", "status_key": "approval_other_use", "row_id": "https://ellumclinic.com/peptides/status#methylene-blue", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "mic-lipo-injection", "canonical_name": "MIC / lipo injection (methionine + inositol + choline, +/- B12)", "aliases": "mic injection;mic b12;lipo injection;lipo b;lipo b12;lipotropic injection;lipo shot;skinny shot;mic shot", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "No approved product; no FDA statement or warning letter found", "compounding_503a": "Choline chloride Category 1 (PCAC 2021 2-11-1 against); methionine no category; inositol no category (only inositol hexanicotinate, Category 3): no verified 503A path; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://api.fda.gov/drug/enforcement.json?search=product_description:\"lipotropic\" https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Compounded nutrient injection blend (not a peptide)", "mechanism": "Nutrient blend marketed for fat processing; no approved claim", "url": "https://ellumclinic.com/peptides/mic-lipo-injection", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#mic-lipo-injection", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "mots-c", "canonical_name": "MOTS-c", "aliases": "mots-c;mots c;motsc;motc;mots c peptide;mitochondrial peptide", "status_label": "Not FDA-approved · advisory vote July 2026 · no FDA decision", "status_class": "under_fda_review", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04", "compounding_as_of": "2026-10-04", "pcac_history": "2026-07-23: recommended 7-5-2 (free base and acetate; uses reviewed: obesity, osteoporosis; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against", "wada_2026": "S4.4.1", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193347/download https://www.fda.gov/media/193342/download https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://youtube.com/live/DhDC0DAYdBI?t=41619", "class": "Mitochondrial-derived peptide (16-aa)", "mechanism": "Mitochondria-encoded peptide acting as a metabolic (AMPK) signal", "url": "https://ellumclinic.com/peptides/mots-c", "status_key": "under_fda_review", "row_id": "https://ellumclinic.com/peptides/status#mots-c", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "mounjaro", "canonical_name": "Mounjaro", "aliases": "mounjaro;mounjaro kwikpen", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA215866, 2022; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high risk for major adverse cardiovascular events)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0", "class": "Brand of tirzepatide", "mechanism": "See tirzepatide", "url": "https://ellumclinic.com/peptides/tirzepatide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#mounjaro", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "n-acetyl-selank", "canonical_name": "N-Acetyl Selank (incl. amidate)", "aliases": "n-acetyl selank;na-selank;n-acetyl selank amidate;acetyl selank", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://api.fda.gov/drug/ndc.json?search=active_ingredients.name:\"N-ACETYL%20SELANK\" https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Acetylated selank analog", "mechanism": "Selank with an acetyl (and in the amidate form an amide) cap, sold as an anti-anxiety nootropic", "url": "https://ellumclinic.com/peptides/n-acetyl-selank", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#n-acetyl-selank", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "n-acetyl-semax", "canonical_name": "N-Acetyl Semax", "aliases": "n-acetyl semax;na-semax;acetyl semax", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/193348/download https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Acetylated semax analog", "mechanism": "Semax with an acetyl cap to resist breakdown, sold as a nootropic", "url": "https://ellumclinic.com/peptides/n-acetyl-semax", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#n-acetyl-semax", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "n-acetyl-semax-amidate", "canonical_name": "N-Acetyl Semax Amidate", "aliases": "n-acetyl semax amidate;na-semax-amidate;semax amidate;nasa peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/193348/download https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Acetylated and amidated semax analog", "mechanism": "Semax capped at both ends to slow breakdown, sold as a nootropic", "url": "https://ellumclinic.com/peptides/n-acetyl-semax-amidate", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#n-acetyl-semax-amidate", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "nac", "canonical_name": "NAC (N-acetylcysteine)", "aliases": "nac;n-acetylcysteine;n-acetyl cysteine", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement under FDA enforcement discretion", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.federalregister.gov/documents/2022/08/02/2022-16499/policy-regarding-n-acetyl-l-cysteine-guidance-for-industry-availability https://www.fda.gov/food/hfp-constituent-updates/fda-issues-response-two-citizen-petitions-nac-dietary-supplements", "class": "Amino-acid derivative (not a peptide)", "mechanism": "Cysteine source for glutathione", "url": "https://ellumclinic.com/peptides/nac", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#nac", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "nad", "canonical_name": "NAD+ (nicotinamide adenine dinucleotide)", "aliases": "nad;nad+;nicotinamide adenine dinucleotide", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA) when oral; injectable is the nad-injectable row", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.federalregister.gov/documents/2019/09/05/2019-18951/amendments-to-the-list-of-bulk-drug-substances-that-can-be-used-to-compound-drug-products-in", "class": "Coenzyme (not a peptide)", "mechanism": "Coenzyme that cells use in their mitochondria", "url": "https://ellumclinic.com/peptides/nad", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#nad", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "nad-precursors", "canonical_name": "NAD+ (oral precursors)", "aliases": "nad supplement;nad precursor;nad+ supplement", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/food/new-dietary-ingredient-ndi-notification-process/submitted-75-day-premarket-notifications-new-dietary-ingredients https://www.regulations.gov/document/FDA-2023-P-0872-2754 https://www.regulations.gov/document/FDA-2022-S-0023-0068 https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=635 https://www.regulations.gov/document/FDA-2018-S-0023-0032 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31a684d0-cd98-4e46-b43a-ccbd17c41559 https://www.regulations.gov/document/FDA-2015-S-0024-1317", "class": "Coenzyme / precursor stack (not a peptide)", "mechanism": "Oral NMN or NR (+TMG) to support NAD+ levels", "url": "https://ellumclinic.com/peptides/stacks/nad-precursors", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#nad-precursors", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "nad-injectable", "canonical_name": "NAD+ injections (Rx)", "aliases": "nad injection;nad+ injection;nad iv;nad shots;nad+ iv drip", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 1 (interim; enforcement discretion)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026", "class": "Coenzyme (not a peptide)", "mechanism": "Cellular energy coenzyme given by injection", "url": "https://ellumclinic.com/peptides/nad#forms", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#nad-injectable", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "naltrexone", "canonical_name": "Naltrexone", "aliases": "naltrexone;naltrexone tablets;vivitrol", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (ReVia NDA018932 1984, disc.; generic 50 mg tablets; Vivitrol NDA021897 2006, extended-release injection; with bupropion in Contrave NDA200063 2014)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-07", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06ff2d5a-e62b-4fa4-bbdb-01938535bc65 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Opioid antagonist (not a peptide)", "mechanism": "Blocks opioid receptors", "url": "https://ellumclinic.com/peptides/naltrexone", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#naltrexone", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "nmn", "canonical_name": "NMN (nicotinamide mononucleotide)", "aliases": "nmn;nicotinamide mononucleotide;nmn supplement", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/food/new-dietary-ingredient-ndi-notification-process/submitted-75-day-premarket-notifications-new-dietary-ingredients https://www.regulations.gov/document/FDA-2023-P-0872-2754 https://www.regulations.gov/document/FDA-2022-S-0023-0068", "class": "NAD+ precursor (not a peptide)", "mechanism": "Converted to NAD+ in cells", "url": "https://ellumclinic.com/peptides/nmn", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#nmn", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "noopept", "canonical_name": "Noopept (omberacetam)", "aliases": "noopept;omberacetam;noopept powder", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved; FDA WL 557887 (2019): Noopept is 'not [a] dietary supplement'", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/crystal-clear-supplements-620285-02042022 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Acylated Pro-Gly dipeptide ester (Russian-developed)", "mechanism": "Small lab-made compound based on two joined amino acids, grouped with racetam-like drugs", "url": "https://ellumclinic.com/peptides/noopept", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#noopept", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "nr", "canonical_name": "NR (nicotinamide riboside)", "aliases": "nicotinamide riboside;nr;niagen;tru niagen", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=635 https://www.regulations.gov/document/FDA-2018-S-0023-0032", "class": "NAD+ precursor (not a peptide)", "mechanism": "Vitamin B3 form converted to NAD+", "url": "https://ellumclinic.com/peptides/nr", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#nr", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "octreotide", "canonical_name": "Octreotide", "aliases": "octreotide;sandostatin;sandostatin lar;mycapssa;bynfezia", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Sandostatin NDA019667, 1988; LAR; oral Mycapssa)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0b7fe9e-7000-4b79-ba3b-291ce92c14f9", "class": "Somatostatin analog (peptide)", "mechanism": "Suppresses growth hormone and gut hormone release", "url": "https://ellumclinic.com/peptides/octreotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#octreotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "oral-minoxidil", "canonical_name": "Oral minoxidil (low-dose)", "aliases": "oral minoxidil;minoxidil tablets;low dose oral minoxidil;loniten", "status_label": "Not FDA-approved for this use", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (prescription only) as tablets for severe high blood pressure only. The first brand, Loniten (approved 1979), has been discontinued; generic tablets are approved. The label has a boxed warning, the most serious kind. Using it for hair loss is off-label, meaning not an approved use. Minoxidil for the scalp (Rogaine) is sold without a prescription and is a different product", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94164/download https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018154", "class": "Vasodilator (potassium-channel opener) (not a peptide)", "mechanism": "Widens blood vessels; hair growth is a side effect", "url": "https://ellumclinic.com/peptides/oral-minoxidil", "status_key": "approval_other_use", "row_id": "https://ellumclinic.com/peptides/status#oral-minoxidil", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "orforglipron", "canonical_name": "Orforglipron", "aliases": "orforglipron;lilly glp-1 pill;ly3502970", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Foundayo NDA220934, 2026-04-01)", "compounding_503a": "Approved-drug component (small molecule; not a peptide)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62", "class": "Small-molecule oral GLP-1 receptor agonist (not a peptide)", "mechanism": "Non-peptide pill that activates the GLP-1 receptor", "url": "https://ellumclinic.com/peptides/orforglipron", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#orforglipron", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ostarine", "canonical_name": "Ostarine (enobosarm, MK-2866)", "aliases": "ostarine;enobosarm;mk-2866;mk2866;mk 2866;gtx-024;ostabolic", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (openFDA: no application); excluded from the dietary supplement definition under 201(ff)(3) (FDA ingredient directory categories 2, 4)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S1.2 (named enobosarm (ostarine))", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/food/dietary-supplements/information-select-dietary-supplement-ingredients-and-other-substances https://www.fda.gov/consumers/consumer-updates/fda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pinnacle-professional-research-dba-pinnacle-peptides-719337-12122025 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dynamic-health-group-dba-sarms-america-719257-12122025 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Selective androgen receptor modulator (SARM), non-steroidal", "mechanism": "Non-steroidal androgen-receptor ligand designed for tissue selectivity", "url": "https://ellumclinic.com/peptides/ostarine", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ostarine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ovagen", "canonical_name": "Ovagen (peptide bioregulator)", "aliases": "ovagen peptide;ovagen", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic peptide (reported by vendors as a tripeptide)", "mechanism": "Peptide sold for liver and gut support (vendors list three amino acids)", "url": "https://ellumclinic.com/peptides/ovagen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ovagen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "oxytocin", "canonical_name": "Oxytocin", "aliases": "oxytocin;pitocin", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Pitocin NDA018261, 1980)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad https://www.fda.gov/media/94164/download", "class": "Posterior pituitary hormone (peptide)", "mechanism": "Triggers uterine contraction", "url": "https://ellumclinic.com/peptides/oxytocin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#oxytocin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ozempic", "canonical_name": "Ozempic", "aliases": "ozempic;ozempic pen;ozempic tablets;ozempic pill", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA209637, 2017; tablets NDA213051, 2026; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, injection; cardiovascular risk reduction in adults with type 2 diabetes at high risk for major adverse cardiovascular events, tablets; reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, injection only)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf", "class": "Brand of semaglutide", "mechanism": "See semaglutide", "url": "https://ellumclinic.com/peptides/semaglutide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#ozempic", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "p21-peptide", "canonical_name": "P021 (P21 peptide)", "aliases": "p021;p21 peptide;p-21 peptide;p21 nootropic", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://api.fda.gov/drug/ndc.json?search=active_ingredients.name:\"PEPTIDE%20B27PD\" https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Adamantane-modified CNTF-derived peptide", "mechanism": "Small peptide-like molecule derived from CNTF, studied in Alzheimer's mouse models", "url": "https://ellumclinic.com/peptides/p21-peptide", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#p21-peptide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "palopegteriparatide", "canonical_name": "Palopegteriparatide", "aliases": "palopegteriparatide;yorvipath", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Yorvipath NDA216490, 2024)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1fa23fd-c434-443e-9a17-5750578c8602", "class": "Long-acting PTH(1-34) prodrug (peptide)", "mechanism": "Steady PTH replacement for hypoparathyroidism", "url": "https://ellumclinic.com/peptides/palopegteriparatide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#palopegteriparatide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pancragen", "canonical_name": "Pancragen (Lys-Glu-Asp-Trp)", "aliases": "pancragen;lys-glu-asp-trp", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tetrapeptide (KEDW)", "mechanism": "Four-amino-acid peptide modeled on pancreas tissue, studied in aged animals", "url": "https://ellumclinic.com/peptides/pancragen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#pancragen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pasireotide", "canonical_name": "Pasireotide", "aliases": "pasireotide;signifor;signifor lar", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Signifor NDA200677, 2012; LAR NDA203255)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74", "class": "Somatostatin analog (peptide)", "mechanism": "Lowers ACTH/cortisol and GH via somatostatin receptors", "url": "https://ellumclinic.com/peptides/pasireotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#pasireotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pe-22-28", "canonical_name": "PE-22-28", "aliases": "pe-22-28;pe 22 28;pe-22-28 peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"PE-22-28\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic peptide (spadin analog)", "mechanism": "Shortened analog of spadin, a TREK-1 potassium-channel blocker studied for mood in mice", "url": "https://ellumclinic.com/peptides/pe-22-28", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#pe-22-28", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "peg-mgf", "canonical_name": "PEG-MGF", "aliases": "peg-mgf;peg mgf;pegylated mgf;pegylated mechano growth factor", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2026-04-22); not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "Scheduled: PCAC 'before the end of February 2027' (no date set)", "wada_2026": "S2.3", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"PEG-MGF\"", "class": "Pegylated IGF-1 splice-variant peptide", "mechanism": "Longer-acting MGF variant marketed for muscle", "url": "https://ellumclinic.com/peptides/peg-mgf", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#peg-mgf", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pentadeca-arginate", "canonical_name": "Pentadeca arginate (PDA)", "aliases": "pentadeca arginate;pda;pda peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"PENTADECA%20ARGINATE\"", "class": "BPC-157-like peptide salt", "mechanism": "Marketed as a BPC-157 alternative", "url": "https://ellumclinic.com/peptides/pentadeca-arginate", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#pentadeca-arginate", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pinealon", "canonical_name": "Pinealon (Glu-Asp-Arg)", "aliases": "pinealon;pinealon peptide;edr peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tripeptide (Glu-Asp-Arg)", "mechanism": "Three-amino-acid peptide studied in cell and animal models of neuron stress", "url": "https://ellumclinic.com/peptides/pinealon", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#pinealon", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "plecanatide", "canonical_name": "Plecanatide", "aliases": "plecanatide;trulance", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Trulance NDA208745, 2017)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe2895bf-71a6-493a-b0ca-e06b2dfefc82", "class": "Guanylate cyclase-C agonist (oral peptide)", "mechanism": "Draws fluid into the gut to relieve constipation", "url": "https://ellumclinic.com/peptides/plecanatide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#plecanatide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pnc-27", "canonical_name": "PNC-27", "aliases": "pnc-27;pnc 27;pnc-27 peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"PNC-27\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic peptide (p53-derived, with a cell-penetrating sequence)", "mechanism": "Studied for binding HDM-2 on cancer-cell membranes in cell and animal models", "url": "https://ellumclinic.com/peptides/pnc-27", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#pnc-27", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pramlintide", "canonical_name": "Pramlintide", "aliases": "pramlintide;symlin;symlinpen;amylin analog", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Symlin NDA021332, 2005); manufacture discontinued (AstraZeneca, FDA drug shortage list, posted 2025-10-27); Drugs@FDA lists every strength Discontinued; listed marketing end date 2027-01-31", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021332 https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Pramlintide%20Acetate%20Injection&st=d", "class": "Amylin analog (peptide)", "mechanism": "Mimics amylin to slow stomach emptying and blunt post-meal glucose", "url": "https://ellumclinic.com/peptides/pramlintide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#pramlintide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "pregnenolone", "canonical_name": "Pregnenolone", "aliases": "pregnenolone;pregnenolone micronized", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Not an approved drug; sold OTC as a dietary supplement", "compounding_503a": "Category 1 (503A); 503B Category 3", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Steroid hormone precursor (neurosteroid; not a peptide)", "mechanism": "Steroid made from cholesterol; the starting point for other steroid hormones", "url": "https://ellumclinic.com/peptides/pregnenolone", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#pregnenolone", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "progesterone", "canonical_name": "Progesterone (incl. oral micronized)", "aliases": "progesterone;prometrium;micronized progesterone;oral micronized progesterone;progesterone in oil;crinone;endometrin;bioidentical progesterone", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Prometrium NDA019781 1998; progesterone-in-oil ANDAs)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cf237ff-c4f8-4faa-a7aa-77599c856889 https://www.fda.gov/media/94164/download", "class": "Progestogen (not a peptide)", "mechanism": "Protects the uterine lining and supports the menstrual cycle", "url": "https://ellumclinic.com/peptides/progesterone", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#progesterone", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "prostamax", "canonical_name": "Prostamax (Lys-Glu-Asp-Pro)", "aliases": "prostamax;prostamaxin;lys-glu-asp-pro", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026 https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tetrapeptide (KEDP)", "mechanism": "Four-amino-acid peptide modeled on prostate tissue, studied in lab models", "url": "https://ellumclinic.com/peptides/prostamax", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#prostamax", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ptd-dbm", "canonical_name": "PTD-DBM (topical hair peptide)", "aliases": "ptd-dbm;ptd dbm", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"PTD-DBM\"", "class": "Synthetic peptide (topical hair-care ingredient)", "mechanism": "Peptide used in topical hair serums; studied for Wnt signalling in mice", "url": "https://ellumclinic.com/peptides/ptd-dbm", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#ptd-dbm", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "rad-140", "canonical_name": "RAD-140 (testolone)", "aliases": "rad-140;rad140;rad 140;testolone;vosilasarm", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved; FDA: SARMs 'cannot be legally marketed in the U.S. as a dietary supplement or drug'", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S1.2 (named RAD140)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/consumers/consumer-updates/fda-warns-use-selective-androgen-receptor-modulators-sarms-among-teens-young-adults https://www.fda.gov/food/dietary-supplements/information-select-dietary-supplement-ingredients-and-other-substances https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/warrior-labz-sarms-655280-06122023 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sports-nutrition-719433-12122025 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Selective androgen receptor modulator (SARM), non-steroidal", "mechanism": "Non-steroidal compound that binds the androgen receptor in a selective way", "url": "https://ellumclinic.com/peptides/rad-140", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#rad-140", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "rapamycin", "canonical_name": "Rapamycin (sirolimus)", "aliases": "rapamycin;sirolimus;rapamune;rapa;rapamycin longevity;low dose rapamycin;fyarro;hyftor", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Rapamune NDA021083 1999 / NDA021110 2000; Fyarro NDA213312 2021; Hyftor gel; generics); label: renal-transplant rejection prophylaxis. Boxed warning. Longevity use is off-label", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=384cb547-55a4-47fc-a0a6-054c18a51b84 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f9bb784-53e2-46f9-a65d-1c6c2a230eaf", "class": "mTOR inhibitor (not a peptide)", "mechanism": "Blocks the mTOR growth pathway; used to prevent transplant rejection", "url": "https://ellumclinic.com/peptides/rapamycin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#rapamycin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "retatrutide", "canonical_name": "Retatrutide", "aliases": "retatrutide;reta;retatrutide peptide;ly3437943;glp-3;triple g", "status_label": "Investigational (phase 3)", "status_class": "investigational", "trial_phase": "3", "fda_status": "Investigational, phase 3, not filed (Lilly plans BLA Q1 2027)", "compounding_503a": "Not eligible (FDA: 'cannot be used in compounding under federal law')", "compounding_as_of": "2026-10-01", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026 https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"RETATRUTIDE\" https://clinicaltrials.gov/study/NCT05929066", "class": "GIP/GLP-1/glucagon triple agonist (peptide)", "mechanism": "Studied for its action on the GIP, GLP-1 and glucagon receptors in large trials", "url": "https://ellumclinic.com/peptides/retatrutide", "status_key": "investigational", "row_id": "https://ellumclinic.com/peptides/status#retatrutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "retatrutide-mots-c-stack", "canonical_name": "Retatrutide / MOTS-c stack", "aliases": "retatrutide mots-c;elite metabolic stack;metabolic super stack", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026", "class": "Stack of 2 entities", "mechanism": "Metabolic stack", "url": "https://ellumclinic.com/peptides/stacks/retatrutide-mots-c-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#retatrutide-mots-c-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "romiplostim", "canonical_name": "Romiplostim", "aliases": "romiplostim;nplate", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Nplate BLA125268, 2008)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c45f9a58-37c1-4f76-8e36-97d38c577037", "class": "TPO receptor agonist (peptibody)", "mechanism": "Stimulates platelet production", "url": "https://ellumclinic.com/peptides/romiplostim", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#romiplostim", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "rybelsus", "canonical_name": "Rybelsus", "aliases": "rybelsus", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA213051, 2019; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high risk for major adverse cardiovascular events)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051", "class": "Brand of semaglutide", "mechanism": "See semaglutide", "url": "https://ellumclinic.com/peptides/semaglutide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#rybelsus", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "saxenda", "canonical_name": "Saxenda", "aliases": "saxenda", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA206321, 2014; weight management)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143", "class": "Brand of liraglutide", "mechanism": "See liraglutide", "url": "https://ellumclinic.com/peptides/liraglutide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#saxenda", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "secretin-human", "canonical_name": "Secretin, human", "aliases": "secretin;human secretin", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (ChiRhoStim, synthetic human secretin; NDA021256, 2004; diagnostic)", "compounding_503a": "Category 3 (since 2023-09-29); 503B Category 3", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.fda.gov/media/94164/download https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021256 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd", "class": "Gut hormone (peptide)", "mechanism": "Stimulates pancreatic bicarbonate secretion", "url": "https://ellumclinic.com/peptides/secretin-human", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#secretin-human", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "selank", "canonical_name": "Selank", "aliases": "selank;selank acetate;tp-7", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category (removed from Cat 2 2024-09-27: nominator meant a different substance); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://web.archive.org/web/20241107074712id_/https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Tuftsin-analog heptapeptide", "mechanism": "Tuftsin analog studied for anxiety", "url": "https://ellumclinic.com/peptides/selank", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#selank", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "semaglutide", "canonical_name": "Semaglutide", "aliases": "semaglutide;sema", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Ozempic NDA209637 2017; Wegovy NDA215256 2021; Rybelsus NDA213051 2019; Ozempic tablets NDA213051 2026; Wegovy tablet NDA218316 2025)", "compounding_503a": "Approved-drug component; shortage resolved 2025-02-21 (503A window ended, PI denied 2025-04-24; 503B ended 2025-05-22); 'essentially a copy' limits apply", "compounding_as_of": "2026-04-01", "pcac_history": "", "wada_2026": "Not prohibited (monitoring)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98 https://www.fda.gov/media/185526/download https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal https://www.wada-ama.org/sites/default/files/2025-09/2026_list_monitoring_program_en_final_clean_september_2025.pdf https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051 https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/213051Orig1s030ltr.pdf", "class": "GLP-1 receptor agonist (peptide)", "mechanism": "Copies the gut hormone GLP-1 and binds its receptor", "url": "https://ellumclinic.com/peptides/semaglutide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#semaglutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "semaglutide-aod-9604-stack", "canonical_name": "Semaglutide / AOD-9604 stack", "aliases": "semaglutide aod-9604;sema aod", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "Fat-loss stack; variants add cagrilintide or MOTS-c", "url": "https://ellumclinic.com/peptides/stacks/semaglutide-aod-9604-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#semaglutide-aod-9604-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "semaglutide-salts", "canonical_name": "Semaglutide sodium / acetate (salt forms)", "aliases": "semaglutide sodium;semaglutide acetate;semaglutide salt", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "FDA: 'not aware of any lawful basis for their use in compounding'", "compounding_as_of": "2026-10-01", "pcac_history": "", "wada_2026": "Not prohibited (monitoring)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss", "class": "Salt forms of semaglutide", "mechanism": "Different chemical form than the approved drug", "url": "https://ellumclinic.com/peptides/semaglutide#forms", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#semaglutide-salts", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "semax", "canonical_name": "Semax", "aliases": "semax;semax peptide;semax heptapeptide", "status_label": "Not FDA-approved · advisory vote July 2026 · no FDA decision", "status_class": "under_fda_review", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04", "compounding_as_of": "2026-10-04", "pcac_history": "2026-07-24: recommended 8-5-1 (free base and acetate; uses reviewed: cerebral ischemia, migraine, trigeminal neuralgia; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193348/download https://www.fda.gov/media/193342/download https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://youtube.com/live/xXM5ecHxlMU?t=28351", "class": "ACTH(4-7) analog heptapeptide", "mechanism": "Lab-made peptide based on a short piece of the hormone ACTH, studied in nerve-cell research", "url": "https://ellumclinic.com/peptides/semax", "status_key": "under_fda_review", "row_id": "https://ellumclinic.com/peptides/status#semax", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "semax-selank-stack", "canonical_name": "Semax / selank stack", "aliases": "semax selank;semax selank stack;russian nootropic stack;russian stack", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://web.archive.org/web/20241107074712id_/https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "Nasal nootropic peptide stack", "url": "https://ellumclinic.com/peptides/stacks/semax-selank-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#semax-selank-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "sermorelin", "canonical_name": "Sermorelin", "aliases": "sermorelin;sermorelin acetate;geref;grf 1-29", "status_label": "FDA-approved, discontinued", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Approved 1990 (Geref NDA019863/NDA020443), discontinued; Drugs@FDA: FR determination not withdrawn for safety or effectiveness", "compounding_503a": "No 503A category; 503B Category 1 as approved-drug component", "compounding_as_of": "2025-03-21", "pcac_history": "", "wada_2026": "S2.2.4", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863 https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443 https://www.fda.gov/media/94164/download https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/innoveix-pharmaceuticals-inc-624782-01262022 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "GHRH analog (peptide)", "mechanism": "Stimulates the pituitary to release growth hormone", "url": "https://ellumclinic.com/peptides/sermorelin", "status_key": "approval_discontinued", "row_id": "https://ellumclinic.com/peptides/status#sermorelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "sermorelin-ghrp-2-stack", "canonical_name": "Sermorelin / GHRP-2 stack", "aliases": "sermorelin ghrp-2;sermorelin ghrp2", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863 https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "GH-axis stack", "url": "https://ellumclinic.com/peptides/stacks/sermorelin-ghrp-2-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#sermorelin-ghrp-2-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "setmelanotide", "canonical_name": "Setmelanotide", "aliases": "setmelanotide;imcivree", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Imcivree NDA213793, 2020)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9", "class": "MC4 receptor agonist (peptide)", "mechanism": "May restore MC4 receptor signaling that curbs appetite in some rare types of obesity", "url": "https://ellumclinic.com/peptides/setmelanotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#setmelanotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "sildenafil", "canonical_name": "Sildenafil", "aliases": "sildenafil;sildenafil citrate;viagra;revatio;generic viagra", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Viagra NDA020895 1998; Revatio NDA021845 2005; generics); label: ED (Viagra), PAH (Revatio)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d905dc8d-917f-4ea3-a4ee-a1ecf6967d4e https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3bb9363e-b28d-4019-8aae-539233dca214", "class": "PDE5 inhibitor (not a peptide)", "mechanism": "Relaxes blood-vessel smooth muscle", "url": "https://ellumclinic.com/peptides/sildenafil", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#sildenafil", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "slu-pp-332", "canonical_name": "SLU-PP-332", "aliases": "slu-pp-332;slu pp 332;slu-pp-332 peptide;slupp332", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"SLU-PP-332\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Small-molecule estrogen-related receptor (ERR) agonist (not a peptide)", "mechanism": "Activates estrogen-related receptors; studied as an 'exercise mimetic' in mice", "url": "https://ellumclinic.com/peptides/slu-pp-332", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#slu-pp-332", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "snap-8", "canonical_name": "SNAP-8 (cosmetic peptide)", "aliases": "snap-8;snap 8;snap8;snap-8 peptide", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"ACETYL%20OCTAPEPTIDE-3\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic peptide (cosmetic ingredient)", "mechanism": "Peptide used in creams to soften expression lines, related to Argireline", "url": "https://ellumclinic.com/peptides/snap-8", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#snap-8", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "somatropin", "canonical_name": "Somatropin (HGH)", "aliases": "somatropin;hgh;human growth hormone;growth hormone;genotropin;norditropin;somatotropin", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (multiple BLAs; e.g. Genotropin, Norditropin)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.2.3", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=62b01d29-90f0-45b2-a0c4-3a750ba36c8a https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Recombinant growth hormone (protein)", "mechanism": "Replaces growth hormone", "url": "https://ellumclinic.com/peptides/somatropin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#somatropin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "spermidine", "canonical_name": "Spermidine", "aliases": "spermidine;spermidine trihydrochloride;wheat germ spermidine", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Not an approved drug; sold as a dietary supplement (GRAS notice GRN 889 closed at notifier's request 2020)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://hfpappexternal.fda.gov/Scripts/Fdcc/index.cfm?set=GRASNotices&id=889 https://www.fda.gov/media/193536/download", "class": "Polyamine (supplement)", "mechanism": "Natural polyamine in wheat germ and soy; studied for autophagy", "url": "https://ellumclinic.com/peptides/spermidine", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#spermidine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "survodutide", "canonical_name": "Survodutide", "aliases": "survodutide;bi 456906", "status_label": "Investigational (phase 3)", "status_class": "investigational", "trial_phase": "3", "fda_status": "Investigational, phase 3, no US submission found", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"SURVODUTIDE\" https://clinicaltrials.gov/study/NCT06066515 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Glucagon/GLP-1 dual agonist (peptide)", "mechanism": "Activates glucagon and GLP-1 receptors", "url": "https://ellumclinic.com/peptides/survodutide", "status_key": "investigational", "row_id": "https://ellumclinic.com/peptides/status#survodutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "tadalafil", "canonical_name": "Tadalafil", "aliases": "tadalafil;cialis;adcirca;daily cialis;tadalafil troche", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Cialis NDA021368 2003; Adcirca NDA022332 2009; generics); label: ED, BPH", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcd8f8ab-81a2-4891-83db-24a0b0e25895 https://www.fda.gov/media/94164/download", "class": "PDE5 inhibitor (not a peptide)", "mechanism": "Relaxes blood-vessel smooth muscle", "url": "https://ellumclinic.com/peptides/tadalafil", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#tadalafil", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "taurine", "canonical_name": "Taurine", "aliases": "taurine", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&search=taurine&type=basic&sort=GRN_No&order=DESC&startrow=1", "class": "Amino sulfonic acid (not a peptide)", "mechanism": "Amino acid involved in cell volume and bile", "url": "https://ellumclinic.com/peptides/taurine", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#taurine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "tb-500", "canonical_name": "TB-500 (thymosin beta-4 fragment LKKTETQ)", "aliases": "tb-500;tb500;tb 500;thymosin beta-4 fragment;lkktetq;thymosin beta 4 fragment", "status_label": "Not FDA-approved · advisory vote July 2026 · no FDA decision", "status_class": "under_fda_review", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04", "compounding_as_of": "2026-10-04", "pcac_history": "2026-07-23: recommended 8-6-1 (free base and acetate; use reviewed: wound healing; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against", "wada_2026": "S2.3", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193349/download https://www.fda.gov/media/193342/download https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://youtube.com/live/DhDC0DAYdBI?t=35315", "class": "Thymosin beta-4 fragment (7-aa peptide)", "mechanism": "Actin-binding piece of thymosin beta-4, studied in tissue research", "url": "https://ellumclinic.com/peptides/tb-500", "status_key": "under_fda_review", "row_id": "https://ellumclinic.com/peptides/status#tb-500", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "teduglutide", "canonical_name": "Teduglutide", "aliases": "teduglutide;gattex;glp-2 analog", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Gattex NDA203441, 2012)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66b69c1e-b25c-44d3-b5ff-1c1de9a516fa", "class": "GLP-2 analog (peptide)", "mechanism": "Grows gut lining absorption in short bowel syndrome", "url": "https://ellumclinic.com/peptides/teduglutide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#teduglutide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "teriparatide", "canonical_name": "Teriparatide", "aliases": "teriparatide;forteo;bonsity;pth 1-34", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Forteo NDA021318, 2002; generics)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab322675-4769-45b0-b146-14fbaa3135d0", "class": "Parathyroid hormone analog (peptide)", "mechanism": "Intermittent PTH signal that builds bone", "url": "https://ellumclinic.com/peptides/teriparatide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#teriparatide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "tesamorelin", "canonical_name": "Tesamorelin", "aliases": "tesamorelin;tesa", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Egrifta BLA022505, 2010; current Egrifta WR)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.2.4", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026 https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nuscience-peptides-llc-733652-08242026 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "GHRH analog (peptide)", "mechanism": "Stimulates the pituitary to release growth hormone", "url": "https://ellumclinic.com/peptides/tesamorelin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#tesamorelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "tesamorelin-ipamorelin-stack", "canonical_name": "Tesamorelin / ipamorelin stack", "aliases": "tesamorelin ipamorelin;tesa ipa;tesa/ipa;tesa ipa blend", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75 https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "GH-axis stack (GHRH analog + ghrelin agonist)", "url": "https://ellumclinic.com/peptides/stacks/tesamorelin-ipamorelin-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#tesamorelin-ipamorelin-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "tesofensine", "canonical_name": "Tesofensine", "aliases": "tesofensine;tesofensine peptide;ns2330", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07; not an approved-drug component", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S6.b (named Tesofensine)", "prescribable_today": false, "as_of": "2026-10-07", "source_urls": "https://www.fda.gov/media/94155/download https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"TESOFENSINE\" https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://clinicaltrials.gov/study/NCT00394667 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Triple monoamine reuptake inhibitor (not a peptide)", "mechanism": "Blocks reuptake of dopamine, noradrenaline and serotonin; studied for appetite and weight loss", "url": "https://ellumclinic.com/peptides/tesofensine", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#tesofensine", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "testagen", "canonical_name": "Testagen", "aliases": "testagen;lys-glu-asp-gly", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tetrapeptide (KEDG, tentative)", "mechanism": "Four-amino-acid peptide sold for testicular support; lab research only", "url": "https://ellumclinic.com/peptides/testagen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#testagen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "testosterone", "canonical_name": "Testosterone (cypionate, enanthate, gels, undecanoate)", "aliases": "testosterone;trt;testosterone replacement therapy;testosterone cypionate;test cyp;testosterone enanthate;test e;testosterone gel;testosterone cream;testosterone injection;testosterone undecanoate;depo-testosterone;xyosted;androgel;aveed;jatenzo;kyzatrex", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Depo-Testosterone ANDA085635; AndroGel NDA021015 2000; Xyosted NDA209863 2018; many ANDAs); label: male hypogonadism; delayed puberty in males (generic testosterone enanthate injection, not Xyosted). DEA Schedule III", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S1.1 (named Testosterone)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81 https://www.federalregister.gov/documents/2025/12/31/2025-24123/fourth-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled-medications https://www.fda.gov/media/94164/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Androgen (anabolic-androgenic steroid) (not a peptide)", "mechanism": "Replaces the main male sex hormone", "url": "https://ellumclinic.com/peptides/testosterone", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#testosterone", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "thymalin", "canonical_name": "Thymalin", "aliases": "thymalin;thymaline;timalin;tymalin", "status_label": "Approved outside the US", "status_class": "approved_outside_us", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; approved in Russia, so S0 does not apply", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-chem-labs-669074-02072024 https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Calf-thymus polypeptide extract", "mechanism": "Mixture of peptides from calf thymus, studied as an immune modulator", "url": "https://ellumclinic.com/peptides/thymalin", "status_key": "approved_outside_us", "row_id": "https://ellumclinic.com/peptides/status#thymalin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "thymogen", "canonical_name": "Thymogen (oglufanide, Glu-Trp)", "aliases": "thymogen;timogen;oglufanide;glutamyl-tryptophan", "status_label": "Approved outside the US", "status_class": "approved_outside_us", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; approved in Russia, so S0 does not apply", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025 https://api.fda.gov/drug/ndc.json?search=active_ingredients.name:\"OGLUFANIDE\" https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Glu-Trp dipeptide", "mechanism": "Two-amino-acid peptide first found in thymus extract; used in Russia as an immune modulator", "url": "https://ellumclinic.com/peptides/thymogen", "status_key": "approved_outside_us", "row_id": "https://ellumclinic.com/peptides/status#thymogen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "thymopentin", "canonical_name": "Thymopentin (TP-5)", "aliases": "thymopentin;tp-5;tp5;timunox", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Pentapeptide, thymopoietin 32-36", "mechanism": "Active five-amino-acid fragment of the thymus hormone thymopoietin", "url": "https://ellumclinic.com/peptides/thymopentin", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#thymopentin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "thymosin-alpha-1", "canonical_name": "Thymosin alpha-1", "aliases": "thymosin alpha 1;thymosin alpha-1;ta1;ta-1;thymalfasin;zadaxin", "status_label": "Approved outside the US", "status_class": "approved_outside_us", "trial_phase": null, "fda_status": "Not FDA-approved (openFDA thymalfasin: no records)", "compounding_503a": "No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component; 503B Category 3", "compounding_as_of": "2026-10-07", "pcac_history": "2024-12-04: against 4-17-0 (free base and acetate; uses reviewed incl. hepatitis B/C, HIV, cancers); FDA staff: against", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"THYMALFASIN\" https://www.fda.gov/media/185642/download https://www.fda.gov/media/183820/download https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.fda.gov/media/94164/download https://web.archive.org/web/20241107074712id_/https://www.fda.gov/media/94155/download https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/organizzazione/1361/farmaci/28364/stampati?ts=RCP https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Thymic peptide (28-aa)", "mechanism": "Thymus peptide studied as an immune modulator", "url": "https://ellumclinic.com/peptides/thymosin-alpha-1", "status_key": "approved_outside_us", "row_id": "https://ellumclinic.com/peptides/status#thymosin-alpha-1", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "thymosin-alpha-1-ll-37-stack", "canonical_name": "Thymosin alpha-1 / LL-37 stack", "aliases": "ta1 ll-37;immune resilience stack", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved as a combination", "compounding_503a": "No category as a combination (see components)", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:\"THYMALFASIN\" https://www.fda.gov/media/94155/download", "class": "Stack of 2 entities", "mechanism": "Immune stack", "url": "https://ellumclinic.com/peptides/stacks/thymosin-alpha-1-ll-37-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#thymosin-alpha-1-ll-37-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "thymosin-beta-4", "canonical_name": "Thymosin beta-4 (full-length)", "aliases": "thymosin beta-4;thymosin beta 4;tb4;tβ4", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Not listed; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "Not voted; PCAC 2026-07-23 covered the LKKTETQ fragment (TB-500) only", "wada_2026": "S2.3", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Actin-sequestering protein (43-aa)", "mechanism": "Full-length actin-binding peptide studied for repair", "url": "https://ellumclinic.com/peptides/thymosin-beta-4", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#thymosin-beta-4", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "thymulin", "canonical_name": "Thymulin", "aliases": "thymulin;thymulin acetate", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 3 (since 2023-09-29); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Thymic peptide (zinc-dependent)", "mechanism": "Thymus hormone involved in T-cell maturation", "url": "https://ellumclinic.com/peptides/thymulin", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#thymulin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "tirzepatide", "canonical_name": "Tirzepatide", "aliases": "tirzepatide;tirz", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Mounjaro NDA215866 2022; Zepbound NDA217806 2023)", "compounding_503a": "Approved-drug component; shortage resolved 2024-12-19 (503A window ended, PI denied 2025-03-05; 503B ended 2025-03-19); 'essentially a copy' limits apply", "compounding_as_of": "2026-04-01", "pcac_history": "", "wada_2026": "Not prohibited (monitoring)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0 https://www.fda.gov/media/184606/download https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal https://www.wada-ama.org/sites/default/files/2025-09/2026_list_monitoring_program_en_final_clean_september_2025.pdf", "class": "GIP/GLP-1 dual receptor agonist (peptide)", "mechanism": "Copies two gut hormones, GIP and GLP-1, and binds both of their receptors", "url": "https://ellumclinic.com/peptides/tirzepatide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#tirzepatide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "tmg", "canonical_name": "TMG (betaine)", "aliases": "tmg;trimethylglycine;betaine", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31a684d0-cd98-4e46-b43a-ccbd17c41559 https://www.regulations.gov/document/FDA-2015-S-0024-1317", "class": "Methyl donor (not a peptide)", "mechanism": "Supplies methyl groups", "url": "https://ellumclinic.com/peptides/tmg", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#tmg", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "triptorelin", "canonical_name": "Triptorelin", "aliases": "triptorelin;trelstar;triptodur", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Trelstar NDA020715, 2000; Triptodur)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "S2.2.1 (males)", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "GnRH agonist (peptide)", "mechanism": "Long-acting GnRH agonist that suppresses sex hormones", "url": "https://ellumclinic.com/peptides/triptorelin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#triptorelin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "urolithin-a", "canonical_name": "Urolithin A", "aliases": "urolithin a;mitopure", "status_label": "Supplement", "status_class": "supplement", "trial_phase": null, "fda_status": "Dietary supplement (DSHEA)", "compounding_503a": "", "compounding_as_of": "", "pcac_history": "", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=791", "class": "Gut-metabolite polyphenol (not a peptide)", "mechanism": "Supports mitophagy (mitochondrial recycling)", "url": "https://ellumclinic.com/peptides/urolithin-a", "status_key": "supplement", "row_id": "https://ellumclinic.com/peptides/status#urolithin-a", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "vip", "canonical_name": "Vasoactive intestinal peptide (VIP)", "aliases": "vip;vasoactive intestinal peptide;vip peptide;aviptadil", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "Category 1 (interim; enforcement discretion); not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "2016-11-03: voted not to include (vote count not confirmed), FDA proposed exclusion 2019-09-05 (84 FR 46688), never finalized", "wada_2026": "", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.federalregister.gov/d/2019-18951 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Neuropeptide", "mechanism": "Studied for its action on smooth muscle in the lungs", "url": "https://ellumclinic.com/peptides/vip", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#vip", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "vasopressin", "canonical_name": "Vasopressin", "aliases": "vasopressin;vasostrict;adh;antidiuretic hormone", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Vasostrict NDA204485, 2014)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b97e5c3e-ca28-4ffa-80af-6c5bdbadaf10 https://www.fda.gov/media/94164/download", "class": "Posterior pituitary hormone (peptide)", "mechanism": "Constricts blood vessels and retains water", "url": "https://ellumclinic.com/peptides/vasopressin", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#vasopressin", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "vesugen", "canonical_name": "Vesugen (Lys-Glu-Asp)", "aliases": "vesugen;lys-glu-asp", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic tripeptide (KED)", "mechanism": "Three-amino-acid peptide modeled on blood-vessel tissue, studied in endothelial-cell models", "url": "https://ellumclinic.com/peptides/vesugen", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#vesugen", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "victoza", "canonical_name": "Victoza", "aliases": "victoza", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA022341, 2010; type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-12", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4", "class": "Brand of liraglutide", "mechanism": "See liraglutide", "url": "https://ellumclinic.com/peptides/liraglutide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#victoza", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "vilon", "canonical_name": "Vilon (Lys-Glu)", "aliases": "vilon;lys-glu;lysylglutamic acid", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved (no drugsfda/DailyMed record)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "Not named; S0 (non-approved substances) applies if no health authority approves it for human use", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/media/94155/download https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Synthetic dipeptide (Lys-Glu)", "mechanism": "Two-amino-acid peptide studied for effects on immune cells in lab models", "url": "https://ellumclinic.com/peptides/vilon", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#vilon", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "vitamin-b12-injection", "canonical_name": "Vitamin B12 injection (cyanocobalamin / hydroxocobalamin)", "aliases": "b12 injection;b12 shot;vitamin b12 injection;cyanocobalamin;cyanocobalamin injection;hydroxocobalamin;nascobal", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (cyanocobalamin injection ANDA080737 and others; hydroxocobalamin ANDA085998; Cyanokit NDA022041); label: B12 deficiency, pernicious anemia", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "Not named", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2fb653d6-e2b2-4969-831b-c0dc37b9c0cc https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3087a39-f218-4f16-a1e7-17c39bb2eb69 https://www.fda.gov/media/94164/download", "class": "Vitamin (cobalamin) (not a peptide)", "mechanism": "Replaces vitamin B12 for blood and nerve function", "url": "https://ellumclinic.com/peptides/vitamin-b12-injection", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#vitamin-b12-injection", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "vosoritide", "canonical_name": "Vosoritide", "aliases": "vosoritide;voxzogo", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Voxzogo NDA214938, 2021)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=228e8560-04a4-4bb1-a81f-29531a9e4d27", "class": "C-type natriuretic peptide analog", "mechanism": "Promotes bone growth plates in achondroplasia", "url": "https://ellumclinic.com/peptides/vosoritide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#vosoritide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "vyleesi", "canonical_name": "Vyleesi", "aliases": "vyleesi", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA210557, 2019; HSDD in premenopausal women)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf", "class": "Brand of bremelanotide", "mechanism": "See bremelanotide", "url": "https://ellumclinic.com/peptides/bremelanotide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#vyleesi", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "wegovy", "canonical_name": "Wegovy", "aliases": "wegovy;wegovy pen;wegovy pill;wegovy tablet", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA215256, 2021; tablet NDA218316, 2025; chronic weight management; cardiovascular risk reduction; noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults, injection only, under accelerated approval)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b", "class": "Brand of semaglutide", "mechanism": "See semaglutide", "url": "https://ellumclinic.com/peptides/semaglutide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#wegovy", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "wolverine-stack", "canonical_name": "Wolverine stack (BPC-157 + TB-500)", "aliases": "wolverine stack;wolverine peptide;bpc tb500 stack;bpc-157 tb-500 blend;bpc + tb500", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved", "compounding_503a": "No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04", "compounding_as_of": "2026-10-04", "pcac_history": "Components each recommended 8-6-1 on 2026-07-23; the blend itself was not voted", "wada_2026": "S0 (BPC-157); S2.3 (TB-500)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/media/193342/download https://www.fda.gov/media/94155/download https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf", "class": "Two-peptide blend", "mechanism": "Two linear peptides combined in one blend", "url": "https://ellumclinic.com/peptides/stacks/wolverine-stack", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#wolverine-stack", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "yk-11", "canonical_name": "YK-11", "aliases": "yk-11;yk11;yk 11;ykarine", "status_label": "Not FDA-approved", "status_class": "not_fda_approved", "trial_phase": null, "fda_status": "Not FDA-approved; FDA ingredient directory category 2; named in FDA fraudulent-products notice (GE Labs Ykarine)", "compounding_503a": "No category; not on 216.23 as of 2026-10-07", "compounding_as_of": "2026-10-07", "pcac_history": "", "wada_2026": "S1.2 (named YK-11)", "prescribable_today": false, "as_of": "2026-10-04", "source_urls": "https://www.fda.gov/food/dietary-supplements/information-select-dietary-supplement-ingredients-and-other-substances https://www.fda.gov/drugs/fraudulent-products/certain-bodybuilding-products-put-consumers-risk-heart-attack-stroke-serious-liver-damage-and-more https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/musclepower-enterprise-ltd-dba-monster-king-and-ge-labs-719339-12122025 https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23", "class": "Steroidal androgen-receptor ligand (sold as a 'SARM')", "mechanism": "Steroid-based compound that binds the androgen receptor; vendors call it a myostatin inhibitor", "url": "https://ellumclinic.com/peptides/yk-11", "status_key": "not_fda_approved", "row_id": "https://ellumclinic.com/peptides/status#yk-11", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "zepbound", "canonical_name": "Zepbound", "aliases": "zepbound;zepbound vial;zepbound kwikpen", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (NDA217806, 2023; weight management; OSA with obesity)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "class": "Brand of tirzepatide", "mechanism": "See tirzepatide", "url": "https://ellumclinic.com/peptides/tirzepatide#forms", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#zepbound", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" }, { "id": "ziconotide", "canonical_name": "Ziconotide", "aliases": "ziconotide;prialt", "status_label": "FDA-approved (Rx)", "status_class": "fda_approved_rx", "trial_phase": null, "fda_status": "Approved Rx (Prialt NDA021060, 2004)", "compounding_503a": "Approved-drug component (not in any 503A category)", "compounding_as_of": "2026-05-14", "pcac_history": "", "wada_2026": "", "prescribable_today": true, "as_of": "2026-10-04", "source_urls": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1 https://www.fda.gov/media/94164/download", "class": "N-type calcium channel blocker (conotoxin peptide)", "mechanism": "Blocks pain signaling in the spinal cord", "url": "https://ellumclinic.com/peptides/ziconotide", "status_key": "fda_approved_rx", "row_id": "https://ellumclinic.com/peptides/status#ziconotide", "version": "2026.10.14", "attribution": "Ellum, Peptide Access Index" } ] }